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Abstract 
  The formation of Fc-fusions, in which biologically active molecules and Fc fragment 
of antibodies are linked each other, is one of the most efficient and successful half-life 
extension technologies that have been developed and applied to peptide and protein 
pharmaceuticals thus far. Fc-fusion compounds are generally produced by recombinant 
methods. However, these cannot be applied to artificial middle molecules, such as 
peptides with non-natural amino acids, unnatural cyclic peptides, or pharmaceutical 
oligonucleotides.  
Here, I developed a simple, efficient, semi-synthetic method for Fc-fusion 
production involving the enzymatic N-terminal extension reaction (i.e., NEXT-A 
reaction), previously developed in our laboratory, and strain-promoted azide-alkyne 
cycloaddition. Reactivity on conjugation site was significantly improved by optimization 
of the N-terminal sequence of Fc protein, and therefore this semi-synthetic method 
achieved quantitative conversion and high selectivity for the N-terminus of the Fc protein. 
Using this method, I demonstrated the preparations of Fc-fusion compounds with various 
kind of middle molecules such as cyclic peptide, peptide incorporating non-natural amino 
acid, and oligonucleotide.  
An Fc-fusion compound prepared by this method showed remarkable long-
circulating plasma half-life in mice, and preferable property of binding affinity to human 
neonatal Fc receptor. Additionally, this Fc-fusion compound also showed durable 
biological activity compared to that of the original peptide without any loss of activity.  
Thus, the proposed method is potentially applicable to a wide range of 
pharmaceutical components. 
 
 
Abstract in Japanese 
中分⼦医薬と呼ばれるペプチドやオリゴ核酸などの分⼦群は、低分⼦医薬の
有する⾼い有効性と、⾼分⼦医薬の有する⾼い特異性という 2 つの特性を併せ
持つと⾔われ、現在の医薬品開発において⾮常に注⽬されている。しかしこれら
の分⼦種に共通する短所として、⽣体内で速やかに代謝・排出されることが課題
とされている。その改善策の中でも最も効果が⾼い⽅法論である Fc-fusion は、
医薬品としての実⽤化に成功しているものの、その製法ゆえに天然アミノ酸の
みで構成された薬理活性物質に適⽤が限られていた。そこで著者は、最近進展の
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著しい bioconjugation を応⽤することで、様々な中分⼦医薬を Fc-fusion にする
ことを可能とする、実⽤的な⽅法を開発した。 
 その調製⽅法として著者は、当研究室にて開発された酵素的 N 末端伸⻑反応
（NEXT-A 反応）を利⽤し、Strain-Promoted Azide-Alkyne Cyclization と組み
合わせることによって、簡便かつ汎⽤的な⽅法で、極めて⾼い化学変換率を実現
した。特に⼀般的にはタンパク質の⽴体障害の影響により、bioconjugation では
⾼い化学変換率を実現することは難しいと考えられていたが、Fc タンパク質の
三次元構造体と反応点との間に距離を持たせることによって、⼩過剰の連結対
象物を使⽤するだけで、bioconjugation がほぼ完結する⽅法論を構築することが
できた。更に著者は、この⽅法論を⽤いることにより、環状ペプチドや⾮天然ア
ミノ酸を含むペプチド、オリゴ核酸などの、遺伝⼦組み換え法では調製できない
薬理活性物質の Fc-fusion 化合物を簡便に調製できることを⽰した。 
 続いて著者は、この⽅法で調製した Fc-fusion が期待する⾎中半減期延⻑効果
を⽰すことを実証した。モデルとして GLP-1 アゴニストペプチドである
Exenatide ないし Exenatide-Fc を、⾃由摂餌下のマウスに腹腔内単回投与した
ところ、元のペプチドである Exenatide の⾎中半減期は 1 時間弱であったのに
対し、Exenatide-Fc は 40〜88 時間と、⾎中半減期が⼤幅に延⻑することを確認
した。加えて本法で調製した Exenatide-Fc は、Exenatide の有する GLP-1 アゴ
ニスト活性を減弱させることなく、持続性が付与されたことを⾒出した。通常は
薬理活性物質をタンパク質などの⼤分⼦に連結するとその⽴体障壁によって活
性が減弱するが、酵素反応および bioconjugation を定量的に進⾏させるために
設けた Fc タンパク質の反応点である N 末端と Fc 部分との間のスペーサーが、
連結した薬理活性物質が標的タンパク質に作⽤するときにも⽴体障壁の回避の
役割をも果たしていることが⽰唆された。 
 本研究では、この bioconjugation による新たな Fc-fusion 化合物の製法が、簡
便な製法であるだけでなく、元の薬理活性物質のもつ活性を残したまま作⽤を
⻑続きさせることができることを⽰した。今後はこの Fc-fusion 製法が様々な中
分⼦医薬にて利⽤されることにより、疾患を抱える⼈々へのより良い治療の提
供に寄与することを期待する。 
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Preface 
 
Bioconjugation is a type of reaction that creates a linkage of biomolecules to other 
biomolecules or artificial compounds, producing a new molecule that combines the 
functions of the two components. This methodology has made possible the assay of 
minute quantity of substances and in vitro/in vivo imaging of specific biological 
substances; however, for decades, there were only limited examples for therapeutic use 
like PEGylated proteins, i.e., PegIntron, Pegasys, Neulasta, and Plegridy. The major 
reason was low selectivity on conjugation sites and conjugation numbers of previous 
bioconjugation methods. Since biomolecules possess many reactive functional groups, 
conventional bioconjugation reactions occur at various positions. In these cases, if 
conjugation occurs near the active site of the original biomolecule, its biological activity 
is impaired. For a long time, acylation and reductive amination on N-terminal amino 
groups of proteins were the representative of site-specific bioconjugation; therefore, 
PEGylated proteins using these reactions have been applied to therapeutic use.  
In 2001, Sharpless et al. proposed a new concept named “click chemistry,” which 
constitutes a type of reaction that proceeds with biomolecules in aqueous solution in low 
concentration. This proposal generated a large number of new studies worldwide; 
bioorthogonal conjugations, those mean conjugation reactions that occur only on the 
targeted site without any side-reaction on off-targeted sites, became the mainstream of 
bioconjugation. This advance in bioconjugation made precise molecular design of 
bioconjugates possible, without the trial-and-error approach common in earlier times. 
Because of this innovative change, it is expected that the application of bioconjugates will 
spread through various industrial fields. Under this scientific background, I started the 
investigation of practical applications of bioconjugation.  
The major objectives of bioconjugation are a combination of two functions of 
bioactive molecules, or to supplement a disadvantage of one bioactive molecule by the 
function of another. The former is, for example, assumed to be a synergistic effect of 
biological activities of the two bioactive molecules, or a reduction of an off-target effect 
by dual specificity. The latter includes delivery of bioactive molecules to diseased sites, 
such as antibody-drug conjugates and bioimaging materials, improvements of 
pharmacokinetic properties of bioactive molecules, such as PEGylated proteins and 
polymer-bound sustained-release formulations, as well as immobilizations of bioactive 
molecules on solid surfaces for immunoassay materials.  
2
 
From another perspective, Fc-fusion compounds have been known as protein 
pharmaceuticals with long circulating plasma half-lives. Compared to other half-life 
technologies such as PEGylation, Fc-fusion compounds show significant half-life 
extension effects due to their mechanism of action. However, most of the Fc-fusion 
compounds were prepared using a recombinant method, and therefore, this molecular 
platform has only been applied to proteins/peptides consisting of canonical amino acids. 
Therefore, I developed an alternative methodology for the preparation of Fc-fusion 
compounds using bioconjugation, in order to apply the unique property of Fc-fusion 
compounds to a wide range of pharmaceutical candidates.  
 
In Chapter 1, the efficacy of middle molecule pharmaceuticals that have recently 
attracted attention and the problem of their short half-lives are described. After that, I 
discuss examples and issues with the preparation methods of Fc-fusion compounds. Next, 
Chapter 2 describes the development of a semi-synthetic method for Fc-fusion 
compounds using bioconjugation. I investigated the design of Fc proteins and the 
selection of an appropriate bioconjugation reaction, and succeeded in creating a 
quantitative preparation method for Fc-fusion compounds. In addition, this method was 
demonstrated that it could be applied to a wide variety of middle molecule 
pharmaceuticals. Chapter 3 describes the results of physicochemical and biological 
evaluation of Fc-fusion compounds prepared using this method. Based on this evaluation, 
it was revealed that Fc-fusion compounds prepared using this method possessed a 
significant half-life extension effect without a decrease of pharmacological activity of the 
original pharmaceutical component. Chapter 4 summarizes these results.  
 
I sincerely hope that this research will contribute to the scientific advances in the 
field of bioconjugation, where practical applications will continue to expand.  
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Abbreviations 
 
α2β1  integrin α2β1 
a.u.  arbitrary unit 
AUC  area under the curve 
AVP1 receptor arginine vasopressin receptor 1 
B2 receptor bradykinin B2 receptor 
Boc  t-butoxycarbonyl 
BSA  bovine serum albumin 
CaSR  Ca2+ sensing receptor 
CBB  Coomassie brilliant blue 
Cmax  maximum drug concentration 
CuAAC  copper-assisted azide-alkyne cycloaddition 
DBCO  dibenzocyclooctyne 
DIBAC  dibenzo-aza-cyclooctyne 
DIPEA  N,N’-diisopropylamine 
DMF  N,N’-dimethylformamide 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
EDC-HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
EDTA  ethylenediaminetetraacetic acid 
EIA  enzyme immunoassay 
ELISA  enzyme-linked immunosorbent assay 
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EPO receptor erythropoietin receptor 
ESI  electrospray ionization 
Fab  fragment antibody 
Fc  fragment crystallizable 
FcRn  neonatal Fc receptor 
Fmoc  9-fluorenylmethoxycarbonyl 
GC-C receptor guanylyl cyclase C receptor 
GLP-1  glucagon-like peptide-1 
GP IIb IIa integrin αIIb/β3 
gp41  glycoprotein 41 
GnRH  gonadotropin releasing hormone 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLA-DR human leukocyte antigen, D-related  
HOBt  1-hydroxybenzotriazole 
HPLC  high-performance liquid chromatography 
I.D.  inside diameter 
KIU  kallikrein inhibitor unit 
LC  liquid chromatogrophy 
MC receptor melanocortin receptor; adrenocorticotropic hormone receptor 
MES  2-(N-morpholino)ethanesulfonic acid 
MHC II  major histocompatibility complex class II 
MPAA  4-mercaptophenylacetic acid 
MS  mass spectrometry 
MWCO  molecular weight cut-off 
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NEXT-A N-terminal extension with L/F-transferase and aminoacyl tRNA 
synthetase 
NK1 receptor neurokinin 1 receptor 
NMR  nuclear magnetic resonance 
NOD2 receptor nucleotide binding-oligomerization domain 2 receptor 
NPR-A  natriuretic peptide receptor-A 
O.D.  optical density 
OT receptor oxytocin receptor 
PBS  phosphate buffered saline 
PEG  poly(ethylene glycol) 
PTH receptor parathyroid hormone receptor 
QMS  quadrupole mass spectrometer 
RNA  ribonucleic acid 
RU  response unit 
SDS-PAGE sodium dodecyl sulfate-poly(acrylamide) gel electrophoresis 
SELEX  systematic evolution of ligands by exponential enrichment 
SPAAC  strain-promoted azide-alkyne cycloaddition 
SPR  surface plasmon resonance 
SST receptor somatostatin receptor 
SST2 receptor somatostatin receptor 2 
t1/2  half-life 
TFA  trifluoroacetic acid 
tmax  time of maximum concentration 
TNFα  tumor necrosis factor α 
TOFMS  time of flight mass spectrometer 
8
 
TRH receptor thyrotropin-releasing hormone receptor 
Tris  tris(hydroxymethyl)aminomethane 
Tris-HCl tris(hydroxymethyl)aminomethane hydrochloride 
tRNA  transfer ribonucleic acid 
UV  ultraviolet 
V2 receptor vasopressin receptor 2 
VEGF  vascular endothelial growth factor 
VIP1 receptor vasoactive intestinal peptide 1 receptor 
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CHAPTER 1 
 
 
 
Introduction 
 
 
 
  
 
1.1 Middle Molecules as Promising Pharmaceutical Candidates 
 
     Middle molecules have attracted substantial attention as a promising molecular 
modality in recent drug discovery research. These molecules, which are placed between 
small synthetic molecules and large proteins, are anticipated to combine the high efficacy 
of the former with the high specificity of the latter.1-4 For example, peptides mediate 
signal transduction in vivo via specific binding to cell surface receptors.2 Because of their 
high specificities and efficacies, these compounds have been applied to cancer treatments, 
metabolic disorders, gastrointestinal diseases, and respiratory indications.1 In addition to 
the achievements towards clinical use of peptides, recent improvements in the 
methodologies of the molecular design of biologically active peptides have expanded the 
possibility of therapeutic use of peptides. The first peptide pharmaceutical was 
corticotropin, approved in 1952, and after that, therapeutic use of peptides was 
widespread with various kinds of natural signaling peptides (Table 1.1.1).5. The number 
of peptide pharmaceuticals remarkably increased in the 1980’s; one of the reasons was 
usage of luteinizing hormone-releasing hormone, isolated and characterized in 1971,6 and 
its derivatives. Then, a wide variety of peptides, e.g., calcitonin,7 somatostatin,8 atrial 
natriuretic peptide,9,10 and exendin-4,11 were discovered from natural sources. Thereafter, 
in addition to traditional lead optimization from a large pool of natural peptides such as 
the above examples, the scope of discovering promising peptide candidates has been 
widened by high-throughput screening using synthetic peptide libraries and phage-
display libraries. The number and diversity of the compounds in peptide libraries have 
been drastically increased by the introduction of non-natural amino acids, which can be 
briefly prepared by artificially expanded genetic codes.12-14 Additionally, compared to 
flexible linear peptides, cyclic peptides are actively researched as a promising modality 
that can improve potency due to their tolerance to proteolysis and entropy advantage in 
receptor binding .15 
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     Oligonucleotides have also attracted attention as new molecular modalities and 
promising pharmaceutical candidates.3,4 Based on the mode of action, oligonucleotides 
are classified into antisense oligonucleotides, aptamers, small interfering RNAs, 
microRNAs, and immunostimulatory oligonucleotide adjuvants (Table 1.1.2).4 Antisense 
oligonucleotides incorporate complementary sequence to target DNAs and RNAs, and 
inhibit the production of disease-causing proteins by binding to the target DNAs and 
RNAs.3 Various antisense oligonucleotides in the fields of hematology and oncology are 
under clinical development, and these therapeutic targets are being extended to 
inflammatory, cardiovascular, and neurological diseases. Another type of pharmaceutical 
oligonucleotide, oligonucleotide aptamers, selectively bind to specific targets and 
modulate their biological activities.16 Due to the characters of specific binding, they are 
also called “chemical antibodies.” Compared to strategies employed to discover 
antibodies using the immunization methodology, oligonucleotide aptamers can be 
obtained by an in vitro selection process, namely systematic evolution of ligands by 
exponential enrichment (SELEX).17-19 Due to this simplistic and exhaustive discovery 
process, oligonucleotide aptamers are recently applied as alternatives to viable antibodies 
in the fields, such as therapeutics, diagnostics, and targeted drug delivery systems.  
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Table 1.1.2. Oligonucleotide pharmaceuticals. (Data source: Clarivate Cortellis)a) 
Name Originator 
Launched 
year 
Indication 
Mechanism of 
Action 
Substitution
Fomivirsen 
Ionis 
Pharmaceuticals 
1999 Cytomegalovirus retinitis Antisense PS oligo 
Pegaptanib 
NeXstar 
Pharmaceuticals 
2005 
Wet age related macular 
degeneration
Aptamer 
PEGylated, 
2’-OMe 
Mipomersen 
Ionis 
Pharmaceuticals 
2013 
Familial 
hypercholesterolemia
Antisense 
PS oligo 
2’-MOE 
Defibrotideb) 
Jazz 
Pharmaceuticals 
2014 Venous occlusive disease Unknown  
Nusinersen 
Ionis 
Pharmaceuticals 
2016 Spinal muscular atrophy Antisense 
PS oligo,  
2’-MOE 
Eteplirsen 
Sarepta 
Therapeutics 
2016 Duchenne dystrophy Antisense 
Morpholino
nucleic acid
Rintatolimod 
Hemispherx 
Biopharma 
2017 
Chronic fatigue syndrome, 
pancreas tumor 
Mismatched 
double stranded 
RNA (dsRNA) 
 
Inotersen 
Ionis 
Pharmaceuticals 
2018 
Familial amyloid 
neuropathy
Antisense 
PS oligo,  
2’-MOE 
Patisiran 
Alnylam 
Pharmaceuticals 
2018 
Familial amyloid 
neuropathy
Interfering RNA 2’-OMe 
Heplisav Dynavax 2018 Hepatitis B 
Vaccine 
adjuvant
PS oligo 
Volanesoren 
Ionis 
Pharmaceuticals 
Registered
Familial 
Chylomicronemia 
syndrome
Antisense 
PS oligo,  
2’-MOE 
a) Abbreviation of Substitution: PS oligo: phosphorothioate backbone; 2’-MOE: methoxyethyl 
substitution on 2’-position of RNA; Morpholino nucleic acid: oligonucleotide consisting of nucleic 
acid possessing a morpholino ring instead of ribose.  
b) Depolymerized product of porcine intestinal mucosal DNA.  
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1.2 Plasma Half-Life Extension Technologies for Middle Molecules 
 
A major obstacle to the therapeutic application of middle molecules is their short 
circulating plasma half-life.20-22 For improvement of the half-lives of the middle 
molecules, several technologies have been developed based on three approaches: 1) 
protection from biodegradation in the blood stream, 2) avoidance of renal clearance, and 
3) recycling via neonatal Fc receptor (FcRn) binding.23 In the first approach, some kind 
of modifications to the molecular structures can be applied. For example, in peptides, 
modification of the amino acid sequence and introduction of non-natural amino acids to 
the protease cleavage site have been successful.24,25 In the case of oligonucleotides, 
modifications of molecular structures, including a non-natural phosphorothioate 
backbone, and modification of the sugar structure are often applied to avoid rapid 
degradation.26 In the second approach, renal excretion of a pharmaceutical molecule 
depends on its molecular size; particularly, compounds with molecular weights smaller 
than 30 kDa usually possess a character of short half-life due to renal excretion.27 
Therefore, several types of modification to increase molecular weight and hydrodynamic 
radius have been applied.20-22 A typical and well-known approach is poly(ethylene 
glycol)-conjugation (i.e., PEGylation), which is a well-established and clinically applied 
method to improve the pharmacokinetic properties of pharmaceutical peptides and 
proteins. For example, as in cases of peginterferon alfa-2b, pegfilgrastim, peginterferon 
alfa-2a, and peginterferon beta-1a, PEGylation has been recognized as a promising option 
for the avoidance of renal clearance. Poly(ethylene glycol) was previously recognized to 
be non-immunogenic; however, generation of anti-PEG antibodies inside patients was 
reported in recent years, and the possibility of decreased therapeutic response in these 
patients is a cause for concern.28 Thus, alternative technologies against PEGylation are 
being investigated. Typical examples of such strategies are the conjugation with 
unstructured protein polymers, namely extended recombinant polypeptides (i.e., 
XTEN)29 and with proline/alanine-rich sequences (i.e., PASylation). 30,31 Finally, the last 
approach is incorporation of moieties that bind to FcRn. As the binding moieties against 
FcRn, Fc fragments of immunoglobulins G1, G2, or G4, or albumin are used. Antibodies 
and albumin possess long half-lives in the body compared with those of other serum 
proteins.32 Their excellent half-lives can be attributed not only to their large molecular 
size, but also to the recycling of these proteins through FcRn binding. Bioconjugation 
with the FcRn binding moieties, Fc fragment, or albumin, imparts the nature of long half-
lives of these moieties to middle molecules. Consequently, Fc- and albumin-fusions have 
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much longer plasma half-lives than the original peptides.23  
 
Table 1.2.1. Typical Half-life Extension Methodologies for Biopharmaceuticals.20-22 
Methodology Conjugation partner Half-life extension mechanism 
PEGylation Poly(ethylene glycol)  Avoidance of renal clearance
PASylation 
Unstructured polypeptide composed of P, 
A, and S 
 Avoidance of renal clearance
XTEN 
Unstructured polypeptide composed of A, 
E, G, P, S, and T 
 Avoidance of renal clearance
ELPylation Repeat sequence of elastin-like peptide  Avoidance of renal clearance
HAPylation 
Homo-amino-acid peptide based on the 
Gly4Ser repetitive unit 
 Avoidance of renal clearance
Fc-fusion 
Fc fragment of human immunoglobulin 
G1 or 4 
 Avoidance of renal clearance
 FcRn recycling 
Albumin-fusion Human serum albumin 
 Avoidance of renal clearance
 FcRn recycling 
Albumin-binding 
Albumin-binding motif (e.g., maleimide, 
binding protein/peptide, and fatty acid) 
 Avoidance of renal clearance
 FcRn recycling 
 
In principle, the half-life extension effect of an Fc-fusion compound is almost 21 
days, similar to the blood half-life of immunoglobulin G1 or G4. Levin et al. summarized 
the actual blood half-lives of clinically-applied Fc-fusion pharmaceuticals.33 In their 
precise review, the blood half-lives of half-molecule Fc-fusion compounds, i.e., alprolix 
and aloctate, do not extend beyond a few days, however, that of Fc-fusion compounds 
possessing native dimeric structures extend to 4 to 14 days. These data indicate that Fc-
fusion compounds are a clinically proven technology, in addition to possessing much 
longer half-lives compared to that of other half-life extension technologies.  
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Figure 1.2.1. Comparison of the half-lives of Fc-fusion pharmaceuticals (blue circles), 
therapeutic mAbs (red squares), and immunoglobulin G1 (green triangle). (Quoted from 
reference 33) 
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1.3 Bioconjugation Methodologies for Fc-Fusion Compounds 
 
     Since etanercept34 was approved for therapeutic use in 1998, many Fc-fusion 
compounds have been used in the clinic (Table 1.3.1). Half-life extension technology 
using the Fc-fusion molecular platform was originally applied to pharmaceutical proteins, 
and then this methodology was applied to pharmaceutical peptides in recent decades. 
Romiplostim is the first-approved peptide-Fc fusion drug used for the therapy of 
thrombocytopenia.35 This Fc-fusion compound has a repeated sequence of the 
thrombopoietin mimetic peptide on its C-terminus.36 Dulaglutide is a Fc-fusion 
compound having glucagon-like peptide 1 on its N-terminus, used for type 2 diabetes 
therapy.37 Glucagon-like peptide 1 is a natural hormone peptide that is secreted in the 
human body, but cannot be used for therapy because of its rapid excretion and enzymatic 
degradation.36 Dulaglutide improved the short half-life of glucagon-like peptide 1, and 
the biological activity of glucagon-like peptide 1 became applicable for therapeutic use.  
     From the viewpoint of molecular design, pharmaceutical proteins and peptides are 
conjugated on the N-terminus of Fc proteins in most Fc-fusion compounds. These 
molecular designs are reasonable because Fab fragments are linked to Fc fragments on 
the N-terminus of Fc fragments in all of natural antibodies. However, only romiplostim 
had the pharmaceutical peptide conjugated to the C-terminus of the Fc protein. This 
characteristic structure was chosen based on the exhaustive screening of conjugation sites 
and linker lengths.36  
     All of the conventional therapeutic Fc-fusion compounds listed in Table 1.3.1 are 
produced as genetic fusion proteins. Most of them are produced by mammalian cells, 
which is reasonable because of the complex folding structures of Fc-fusion compounds. 
Only romiplostim is produced by microbial fermentation, and the refolding process is 
applied for the construction of the bioactive three-dimensional structure.38 Furthermore, 
the molecular platform of an Fc-fusion, prepared by recombinant technology, is limited 
to conventional peptides composed of the canonical 20 amino acids.  
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Table 1.3.1. Fc-fusion compounds for therapeutic use. (Data source: Clarivate Cortellis) 
Name Pharmaceutical component FDA 
approval year 
Host cell
Etanercept Tumor necrosis factor 
receptor 
(Protein) 1998 CHO 
Alefacept Lymphocyte function-
associated antigen 3
(Protein) 2003 CHO 
Abatacept Cytotoxic T-lymphocyte 
antigen 4 (mutant)
(Protein) 2005 CHO 
Rilonacept Interleukin-1 receptor (Protein) 2008 CHO 
Aflibercept Vascular endothelial 
growth factor receptor 1 
and 2 
(Protein) 2011 CHO 
Belatacept Cytotoxic T-lymphocyte 
antigen 4 
(Protein) 2011 CHO 
Ziv-aflibercept Vascular endothelial 
growth factor receptor 1 
and 2 
(Protein) 2012 CHO 
Efmoroctocog 
alfa 
Factor VIII (Protein) 2014 HEK293
Eftrenonacog 
alfa 
Factor IX (Protein) 2014 HEK293
Romiplostim Thrombopoietin-binding 
peptide 
(Peptide) 2008 E. coli 
Dulaglutide Glucagon-like peptide-1 
analog 
(Peptide) 2014 CHO 
 
In the field of antibody-drug conjugates, increasing attempts to apply bioconjugates 
for therapeutic use were recently conducted.39 With such a background, Mezo et al. 
developed the semi-synthetic method for Fc-fusion compounds using native chemical 
ligation with an Fc protein possessing a Cys residue on its N-terminus. It is well-known 
that interchain disulfides of immunoglobulin G1 antibodies can be easily reduced under 
mild reducing conditions.40 They applied this reduction to an Fc protein possessing a Cys 
residue on its N-terminus, and following native chemical ligation41 with a peptide 
thioester, this resulted in a peptide-Fc fusion compound. Then, the dimeric structure was 
reconstructed by autooxidation. This approach is appropriate for protein conjugation to 
maintain its complex structure because all conversions proceed under mild conditions. 
However, the product was the mixture of mono- and di-adducts using 5 molar excess of 
peptide thioester. Therefore, the manufacturing cost was expensive due to the use of a 
large excess of material, and purification.  
23
 
 
 
Scheme 1.3.1. Schematic illustration of the semi-synthetic route of an Fc-fusion 
compound by Mezo et al.41 
24
 
 
Expressed protein ligation is also known as an advanced method of native chemical 
ligation for application to proteins. This methodology utilizes the character that intein is 
automatically cleaved via translocation to thioester, and a new peptide bond is formed by 
replacing this thioester with the N-terminal Cys of other compounds.42 Thereby, this 
methodology made protein conjugation on its C-terminus possible. However, fusion 
proteins between target proteins and inteins are sometimes unstable, resulting in their 
hydrolysates. As a solution of this unfavorable hydrolysis, streamlined expressed protein 
ligation was developed.43 A certain type of intein can be divided into two protein parts. 
Each single protein part and its fusion protein are stable; however, when these two protein 
parts are mixed, they act as one intein. Frutos et al. reported the method for Fc-fusion 
compounds using the DnaE intein from Anabaena variabilis as a motif for the split intein, 
named streamlined expressed protein ligation,44 and achieved suppression of the 
hydrolysis of the intein. However, more than 20 molar excess of peptide material 
possessing a Cys residue on its N-terminus was necessary in this method, and therefore 
the issue of medical economics persisted.  
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Scheme 1.3.2. Schematic illustration of the semi-synthetic route of an Fc-fusion 
compound by Frutos et al.44 
 
     Thanos et al. reported the expression of Fc proteins incorporating non-natural 
amino acids on various positions by amber suppression and evaluation of the conjugation 
efficiency on these non-natural amino acid residues.45 However, the efficiency of protein 
expression by amber suppression was lower than that of usual protein expression, and the 
addition of large amounts of non-natural amino acids to the fermentation media was 
necessary. Therefore, the issue of medical economics also persisted in this approach.  
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Scheme 1.3.3. Schematic illustration of the semi-synthetic route of an Fc-fusion 
compound by Thanos et al.45 
 
     Kim et al. developed the semi-synthetic method of Fc-fusion compounds via 
reductive amination using commercially available PEG linkers incorporating two 
aldehyde groups.46 Although the pKa values of ε-amines of Lys are 9.3 to 9.5, those of α-
amines are 7.6 to 8.0 in usual proteins and peptides,47 and therefore the α-amines of 
proteins and peptides can be selectively conjugated via reductive amination at a neutral 
pH. The features of their molecular design of Fc-fusion compounds are the insertion of a 
PEG linker between the Fc protein and the pharmaceutical component, and the loading 
of one pharmaceutical component per dimeric Fc protein. To achieve this conjugation 
ratio, they used a large excess of Fc protein, and therefore, the issue of cost persisted. 
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Scheme 1.3.4. Schematic illustration of the semi-synthetic route of an Fc-fusion 
compound by Kim et al.46 
 
     Iwamoto et al. reported the method using glycans as conjugation sites.48 An azide 
group was incorporated into the glycans of an Fc protein via two steps of glycan 
remodeling using EndoS and azido-tagged oxazoline, and then the pharmaceutical 
component was conjugated via strain-promoted azide-alkyne cycloaddition. This 
enzymatic incorporation of conjugation sites achieved high site-selectivity. The glycans 
are linked to N297 of human immunoglobulin G1,49 and therefore this conjugation 
position is close to the binding site of the neonatal Fc receptor.50 Because the plasma half-
lives of antibody-related pharmaceuticals depend on their binding affinities to neonatal 
Fc receptor,51 conjugation of a pharmaceutical component to glycan may decrease the 
plasma half-life of this Fc-fusion compound. In addition, the use of a large amount of 
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expensive azido-tagged oxazoline is an issue from an economical viewpoint.  
 
 
Scheme 1.3.5. Schematic illustration of the semi-synthetic route of an Fc-fusion 
compound by Iwamoto et al.48 
 
     As another approach, White et al. reported the conjugation on the C-terminus of an 
Fc protein using sortase.52 This enzymatic conjugation method using sortase A proceeded 
on the sortase A recognition tag, i.e. LPXTG sequence, with high site-selectivity. 
However, this method requires a large amount of a pharmaceutical component, a coupling 
partner, and sortase A, therefore it is not practical. 
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Scheme 1.3.6. Schematic illustration of the semi-synthetic route of an Fc-fusion 
compound by White et al.52 
 
Considering the effect of plasma half-life extension of an Fc-fusion compound, it 
is a preferable molecular design to set the conjugation site away from the binding site to 
the neonatal Fc receptor. Since natural antibody exerts the effect of plasma half-life 
extension even when the Fab protein is linked to the N-terminus of the Fc protein, it stands 
to reason to set the conjugation site at the N-terminus of the Fc protein to maintain its 
long plasma half-life.  
Each group developed their semi-synthetic methods for Fc-fusion compounds by 
site-specific conjugations; however, issues on practical use and cost remained. Here, to 
expand the application of this Fc-fusion molecular platform, I developed an alternative 
method for producing Fc-fusion compounds incorporating artificial pharmaceutical 
components, which is similar to most other emerging middle molecules. In this semi-
synthetic method, I used an N-terminal extension reaction with leucyl/phenylalanyl-
tRNA-protein transferase53 and aminoacyl-tRNA synthetase (NEXT-A), previously 
developed in our laboratory.54-56 Additionally, I verified that the Fc-fusion compound 
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produced by this method showed a significant extension of half-life and retained the 
biological potency of the original pharmaceutical component. 
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CHAPTER 2 
 
 
 
Semi-Synthetic Studies of Fc-Fusion Compounds 
 
 
 
  
 
2.1 Site-Specific Conjugations on the N-Termini of Proteins 
 
Many types of N-terminal conjugations of proteins have been developed because 
of their many applications in protein labeling and generation of fusion proteins (Table 
2.1.1). The most well-known methods are Nα-selective amidation and alkylation in weak 
acidic conditions, based on the specific pKa value of the α-amino group versus the ε-
amino groups of lysine side-chains.47 These methods are widely used in the preparation 
of N-terminal PEGylated protein pharmaceuticals.57 Additionally, oxime formation and 
reductive amination of N-glyoxyl proteins are also familiar.58,59 For these conjugations, 
N-glyoxyl proteins can be prepared by NaIO4 oxidative cleavage of proteins possessing 
Ser residues on their N-termini, however application of this conversion is limited in the 
case of glycoproteins due to side reactions of oxidative cleavage of glycan structures.  
In recent years, the applications of native chemical ligation and expressed protein 
ligation have frequently been reported.60 The advantage of this method is the formation 
of a natural peptide bond; therefore, many studies have been done to prepare proteins 
from peptide fragments.61 I also used native chemical ligation to prepare Fc proteins with 
different N-terminal chain lengths in a later chapter. Exhaustive expression of these 
protein variants is often challenging; however, preparation by native chemical ligation is 
more efficient if a Cys residue is incorporated near the N-terminus of the common 
sequence of these proteins.  
Some enzymatic conjugations are also applied to bioconjugation. In the case of N-
terminal site-specific conjugation, transglutaminase62 and sortase63 are used for 
substitutions on the N-terminal tag sequences of proteins. However, conjugation only on 
the Nα-amino group proceeds by subtilisin,64 and no tag sequence is required if the N-
terminal sequence of the protein substrate is preferable for subtilisin.  
Compared to these methods, the NEXT-A reaction is useful because several types 
of non-natural amino acids possessing various bio-orthogonal functional groups can be 
incorporated on to the N-terminus of the protein, and therefore various kinds of 
bioconjugation reactions can be applied to the proteins generated by NEXT-A reactions.   
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2.2 Design of the N-Terminus Fc Protein 
 
An Fc fragment of antibodies is a large molecule with a complex three-dimensional 
conformation. Site-specific bioconjugation to such a large molecule is usually challenging, 
because reactivity of a functional group in proximity to a large protein is interfered by 
steric hindrance of protein. Thus, I investigated the effect of chain lengths between the N-
terminus conjugation site and Fc protein on the reactivity of bioconjugation.  
In general, protein expression depends on various factors, such as amino acid 
sequence, folded structure, expression system, and design of DNA construct. Therefore, 
exhaustive expression of the proteins possessing different sequences used for the 
investigation is challenging. Therefore, I prepared Fc proteins with N-terminal Lys (Lys-
Fc) from a common Fc protein with N-terminal Cys (Cys-Fc) by native chemical ligation.  
Five peptide thioesters with different chain lengths (1a–e) were prepared by solid-
phase peptide syntheses using a general Fmoc method following thioesterification. Cys-
Fc (2) was expressed by HEK293 cells. Native chemical ligations between the peptide 
thioesters and Cys-Fc resulted in five Lys-Fcs with varying chain lengths, between N-
terminal Lys and the Fc fragment (3a–e, in Figure 2-2-1).41 During the expression of Cys-
Fc, large numbers of deficit proteins at the N-terminal Cys or Cys-Pro of Fc protein were 
also generated; however, these impurities were removed after conversion to Lys-Fc by 
cation exchange chromatography (Figure 5.2.2 in Experimental section). 
 
Subsequently, the reactivities of the different Lys-Fc proteins in the sequential 
incorporation of (4-azido)phenylalanine at the N-terminus via the NEXT-A reaction and 
following strain-promoted azide-alkyne cycloaddition (SPAAC) with mPEG-
dibenzocyclooctyne (PEG-DBCO) were investigated (Figure 2-2-2). Lys-Fc proteins with  
shorter chains were converted in moderate yields, but residual Lys-Fcs were still observed. 
On the contrary, a Lys-Fc with a chain length of 15 amino acids resulted in a quantitative 
conversion, that is, no unreacted Lys-Fc was observed. These results suggest that a chain 
length of 15 amino acids between the N-terminal Lys and the folded Fc protein is 
necessary to avoid the effect of steric hindrance of Fc protein at the reaction site, i.e. the 
N-terminal Lys. 
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Figure 2.2.1. Semi-syntheses of Fc proteins with different chain lengths, from N-terminal 
Lys to the Fc fragment. 
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Figure 2.2.2. Optimization of the amino acid chain lengths at the N-terminus of the Fc 
protein. A) Reaction scheme for bioconjugation of Lys-Fc proteins with different chain 
lengths via the NEXT-A reaction and SPAAC. B) SDS-PAGE of the reaction mixtures 
after SPAAC. Lanes 1, 2, and 3 show the molecular-weight marker, initial Lys-Fc protein, 
and reaction mixture, respectively. The solid and hollow arrows indicate PEG-Fc 
conjugates (reaction product) and residual initial Lys-Fc proteins, respectively. 
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2.3 Selection of a Bioconjugation Reaction 
 
     One of the advantages of the NEXT-A reaction is that various types of non-natural 
amino acids can be incorporated onto the N-termini of peptides/proteins. This allows us 
to choose the subsequent bioconjugation reaction. Various types of bioconjugations have 
been reported; however, the reaction rate differs for each reaction,69 and the amount of 
materials and reagents required for the bioconjugation depends on the reaction rate. From 
the viewpoint of the production process of pharmaceuticals, the usage of a large excess 
of materials and reagents results in cost-increases, making it impossible to deliver the 
medicine to patients.  
     A variety of non-natural amino acids available for bioconjugations have been 
demonstrated to be applicable to NEXT-A reactions in our laboratory.54,55 Therefore, 
screening of the bioconjugation suitable for the conjugation to the Fc protein was 
investigated using the Fc protein possessing the 15 amino acids’ spacer between the N-
terminal Lys and the folded Fc protein (Lys-Fc). Using the NEXT-A reaction, various 
kinds of phenylalanine derivatives were incorporated onto N-termini of proteins/peptides, 
and then bioconjugations appropriate to the functional groups of the phenylalanine 
derivatives were carried out (Table 2.3.1).  
S-Alkylation is one of the most cost-efficient bioconjugations because both of the 
coupling partners, haloalkanes and thiols, can be economically prepared. However, all of 
the trials with S-alkylations resulted in only moderate yields. Surprisingly, S-alkylation 
of a Fc protein possessing 4-(chloroacetamido)phenylalanine gave the best conversion 
yield in various kinds of 4-(haloacetamido)phenylalanine. It was suggested that 
hydrolysis of the haloacetyl moiety caused inactivation of 4-
(haloacetamido)phenylalanine (data not shown). Copper-catalyzed azide-alkyne 
cyclization (CuAAC) is also an economical bioconjugation method. However, it also 
resulted in low yields. Only when using SPAAC was there complete conversion of Lys-
Fc by these sequential reactions. Therefore, I applied the SPAAC reaction for my semi-
synthetic method for Fc-fusions.   
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Table 2.3.1. Screening of bioconjugation reactions for Fc-fusion compounds.   
 
 
 
 
 
 
  
Bioconjugation
reaction
X group Coupling partner Conversion
SPAAC ‐N3 >99%
‐N3 >99%
CuAAC ‐N3 19%
S‐Alkylation ‐NHCOCH2Cl 49%
‐NHCOCH2Br 15%
‐NHCOCH2I 17%
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2.4 Application to Various Middle Molecules 
 
     This preparation method for Fc-fusion compounds was developed with the 
intention of applying it to middle molecule pharmaceuticals. Thus, applicability of this 
method to middle molecule pharmaceuticals was investigated using peptides and 
oligonucleotides as representatives of middle molecule pharmaceuticals.  
 
 
2.4.1 Peptide-Fc Fusion Compounds 
 
 
Figure 2.4.1. Structures of pharmaceutical peptides investigated in the Fc-fusion semi-
syntheses. The structures of the original active peptides, linkers, and conjugation 
components are shown in black, red, and blue, respectively (DBCO; 
dibenzocyclooctyne). 
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Fc-fusion compounds of the middle molecules were prepared by modifying the 
Lys-Fc with a spacer of 15 amino acids as described above. At first, Exenatide, which 
is a well-known glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes 
therapy,70 was chosen as a representative peptide middle molecule. Peptide 4 (Figure 
2.4.1), which consisted of the Exenatide peptide, was prepared by solid-phase peptide 
synthesis followed by Michael addition of DBCO-maleimide. An Fc protein 
incorporating azide group (N3-Fc) was prepared using the NEXT-A reaction. 
Conjugation between peptide 4 and N3-Fc using SPAAC yielded the Exenatide-Fc 
fusion compound as a homodimeric product; no residual N3-Fc was observed (Figure 
2.4.2A). The reaction mixture was purified by size-exclusion chromatography to obtain 
Exenatide-Fc with a yield of 87%. The detailed structure of Exenatide-Fc was 
unambiguously identified by mass spectrometry, including its two glycoforms, G0F 
and G1F glycan, depending on the glycoforms of Lys-Fc (Figure 2.4.2B). Sequential 
conversion of NEXT-A reaction and SPAAC proceeded under mild reaction conditions; 
therefore, the homodimeric structure of Lys-Fc was retained in Exenatide-Fc, and  
only minimal amount of generated aggregates were observed (Figure 2.4.2C). Usually 
a large excess of reagents or fragments is usually required to complete bioconjugation 
with a large protein, such as an Fc protein.41,52 However, this semi-synthetic method 
only required two equivalents of peptide 1 to complete the SPAAC reaction. 
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Figure 2.4.2. Detailed identification of Exenatide-Fc. (A) SDS-PAGE of the reaction 
mixture of strain-promoted azide-alkyne cycloaddition under reducing (left) and non-
reducing (right) conditions. Lanes 1, 2, and 3 show the molecular-weight marker, N3-
Fc, and reaction mixture, respectively. (B) Deconvoluted mass spectrum of purified 
Exenatide-Fc under reducing condition. (C) Size-exclusion chromatogram of 
Exenatide-Fc at 280 nm. 
 
Abarelix,71 a gonadotropin-releasing hormone antagonist containing various 
types of non-natural amino acids and a cyclic RGD peptide,72,73 which is an adhesive 
molecule against integrin αvβ3, were chosen as representative examples of non-natural 
peptides. Fc-fusion compounds of these peptides cannot be prepared by traditional 
recombinant technology due to incorporation of non-canonical amino acids. However, 
employing this method, Abarelix-DBCO (5) and cyclic RGD peptide-DBCO (6) 
generated the corresponding Fc-fusion compounds as sole products (Figure 2.4.3). 
These Fc-fusion compounds were purified by affinity chromatography using Protein A, 
and the mass numbers of the products agreed well with theoretical values. In protein 
preparation, removal of impurities with properties similar to those of the product (e.g., 
unreacted Lys-Fc) is quite difficult; therefore, quantitative conversion is strongly 
desired for bioconjugation. 
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Figure 2.4.3. SDS-PAGE of SPAAC conjugations with peptide-DBCO and N3-Fc. (A) 
Abarelix-DBCO. (B) Cyclic RGD peptide-DBCO. Lanes 1, 2, and 3 show molecular-
weight marker, N3-Fc, and SPAAC reaction mixture, respectively.  
 
 
2.4.2 DNA Aptamer-Fc Fusion Compounds 
 
 
Figure 2.4.4. Structures of pharmaceutical oligonucleotides investigated in the Fc-
fusion semi-syntheses. The structures of the original active oligonucleotides, linker, 
and conjugation component are shown in black, red, and blue, respectively (DBCO, 
dibenzocyclooctyne; anti-TNFα, anti-tumor necrosis factor alpha; anti-VEGF, anti-
vascular endothelial growth factor). 
 
Next, preparation of oligonucleotide-Fc fusion compounds was investigated. The 
anti-tumor necrosis factor alpha74 and anti-vascular endothelial growth factor75 DNA 
aptamers were converted to DNA aptamer-DBCOs 7 and 8, respectively. These 
compounds were also successfully conjugated to N3-Fc protein to prepare the 
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corresponding Fc-fusion compounds (i.e., oligonucleotide-protein chimeric molecules) 
in a similar manner. The conjugation of the DNA aptamers to N3-Fc was confirmed by 
increase in the molecular weights appropriate to the addition of the DNA aptamers as 
observed by SDS-PAGE (Figure 2.4.5). In addition, the bands of the adducts were 
stained by both protein- (SYPRO® Ruby) and DNA-detecting (SYBR® Safe) reagents, 
suggesting the generation of DNA aptamer-Fc fusion compounds (Figure 2.4.5). 
Conventional antibody pharmaceuticals are usually discovered, based on an 
immunological response of immunized animals; therefore, antibodies from highly toxic 
or non-immunogenic antigens are difficult to obtain.76 Because oligonucleotide 
aptamers can be produced artificially (i.e., SELEX),76 the semi-syntheses of 
oligonucleotide aptamer-Fc fusion compounds can create “chemical antibody” 
molecules without having to depend on conventional immunization methods. 
 
 
Figure 2.4.5. SDS-PAGE of SPAAC conjugations with DNA aptamer-DBCO and N3-
Fc. (A), (B), and (C) show conjugation with anti-TNF α aptamer-DBCO. (D), (E), and 
(F) show conjugation with anti-VEGF aptamer-DBCO. In (A) and (D), the excitation 
wavelength was 520 nm, and emission filter was 605BP40. In (B) and (E), the 
excitation wavelength was 460 nm, and emission filter was 525BP20. (C) and (F) are 
overlay pictures of (A) and (B), and (D) and (E), respectively. Lanes 1, 2, 3, and 4 show 
molecular-weight marker (XL-Ladder Broad, APRO Life Science Institute, Inc.), 
DNA-aptamer-DBCO, N3-Fc, and SPAAC reaction mixture, respectively.  
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CHAPTER 3 
 
 
 
Biological Efficacy of Exenatide-Fc 
 
 
 
  
 
3.1 Pharmacokinetic Studies of Exenatide-Fc 
 
The purpose of applying the Fc-fusion molecular platform is to impart the long 
half-life of antibodies to other pharmaceutical compounds. In addition to avoiding renal 
clearance through their large molecular size, Fc-fusion molecules can undergo recycling 
through FcRn binding. All proteins in the blood stream are imported into cells by 
pinocytosis. Most proteins are transported to the lysosome and degraded by proteolysis; 
however, antibodies or antibody-related compounds, i.e., Fc-fusion compounds, bind to 
FcRn under acidic conditions in the endosome. FcRn-bound components are finally 
released again under neutral pH in the blood stream, due to low binding affinity to FcRn 
in neutral conditions. Thus, the long half-lives of Fc-fusions can be explained by their 
binding properties of Fc to FcRn. 
Therefore, the pharmacokinetics of an Fc-fusion compound prepared by the 
developed semi-synthetic method were evaluated using the Exenatide-Fc fusion derived 
from the Lys-Fc directly expressed by Expi293F™, as a proof of concept. The 
pharmacokinetic effects of Exenatide and our Exenatide-Fc fusion compound were 
investigated in male C57BL/6J mice. The mice were given a single dose of Exenatide or 
Exenatide-Fc via intraperitoneal administration, and plasma was obtained from blood 
samples following aprotinin treatment and centrifugation. The plasma concentrations of 
Exenatide or Exenatide-Fc were analyzed by ELISA. The Fc-fusion compounds prepared 
using the semi-synthetic method are homodimers and consequently possess two 
pharmaceutical components. Thus, the molar concentration of Exenatide-Fc was based 
on the monomer to facilitate the comparison with that of Exenatide.  
Exenatide underwent fast clearance with a calculated half-life of 0.9 h based on a 
few data points (Figure 3.1.1 and Table 3.1.1). This result was consistent with the 
previously reported terminal half-life (1.7–1.9 h).77,78 In contrast, Exenatide-Fc displayed 
a significant increase in terminal circulation half-life (40.4–87.8 h, 24–52-fold vs. 
Exenatide), which was much longer than that obtained using other half-life extension 
technologies.77-79 Additionally, the maximum concentration and area under the curve of 
Exenatide-Fc evidenced a linear dose-dependent relationship (Table 3.1.1), suggesting 
these long half-lives were the nature of Exenatide-Fc, not a saturation of drug metabolism.  
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Figure 3.1.1. Plasma concentrations of Exenatide and Exenatide-Fc over time after 
intraperitoneal administration. The doses were as follows: Exenatide (25.0 nmol/kg), 
Exenatide-Fc L (3.13 nmol/kg), Exenatide-Fc M (12.5 nmol/kg), and Exenatide-Fc H 
(25.0 nmol/kg). The data are presented as mean ± standard deviation (n = 2–3 for each 
group), and the error bars that are not visible are smaller than the size of the marker. For 
Exenatide and Exenatide-Fc L, the final clearance rates are represented by dotted lines 
because the plasma concentrations promptly fell below the quantification limit. 
 
Table 3.1.1. Pharmacokinetic profiles of Exenatide and Exenatide-Fc. 
Substrate Exenatide Exenatide-Fc 
Dose (nmol/kg) 25.0 3.13 12.5 25.0 
Maximum concentration 
(Cmax, nmol/L) 
13.3 3.52 51.0 100 
Maximum concentration 
time (tmax, h) 
1 2 8 8 
Half-life (t1/2, h) 0.928 43.8 40.4 87.8 
Area under the curve 
(AUC0-t , nmol·h/L) 
16.39 70.78 2714 5736 
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This remarkable half-life extension can also be explained by the recycling 
mechanism involving FcRn binding, as indicated by the favorable binding of Exenatide-
Fc to human FcRn observed in ligand binding analyses.51,80,81 
The KD value of trastuzumab against FcRn was calculated as 400 nM at pH 6.0 with 
a negligible affinity at pH 7.4 in this system. In contrast, the KD value of Exenatide-Fc 
was calculated as 52.5 nM at pH 6.0, with negligible binding at pH 7.4, although there 
was a possibility that the calculated KD value of Exenatide-Fc was estimated to be larger 
than the true value because of the unreached association phase to plateau. This unreached 
association phase also caused moderate curve-fitting (i.e., a large chi-square value) of 
Exenatide-Fc. A smaller KD value of Exenatide-Fc than trastuzumab at pH 6.0 suggested 
that Exenatide-Fc had higher affinity to human FcRn than general human 
immunoglobulin G1. Negligible binding affinity to FcRn in neutral conditions was a 
desirable property for the recycling of Exenatide-Fc. Therefore, it was suggested that 
Exenatide-Fc would have a similarly long half-life to antibodies in humans. 
 
 
Figure 3.1.2. Surface plasmon resonance analysis of trastuzumab. (A) Sensorgrams of 
trastuzumab binding to human FcRn. (B) Results of curve fitting with steady-state 
analysis. 
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Figure 3.1.3. Surface plasmon resonance analysis of Exenatide-Fc. (A) Sensorgram of 
Exenatide-Fc binding to human FcRn at pH 6.0. (B) Sensorgram of Exenatide-Fc binding 
to human FcRn at pH 7.4. (C) Results of curve fitting with steady-state analysis. 
 
Table 3.1.2. Calculated affinity parameters against neonatal Fc receptor. 
Trastuzumab Exenatide-Fc 
pH 6.0 pH 7.4 pH 6.0 pH 7.4 
KD (nM) 400 negligible 52.5 negligible
Rmax (a.u.) 87.9 - 72.2 - 
Chi-square 0.2 - 4.9 - 
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3.2 Evaluation of the in vitro and in vivo Biological Activities of Exenatide-Fc 
 
The biological activities of peptides conjugated to a large protein, such as an Fc 
protein are often reduced, because steric hindrance of protein moieties inhibit the binding 
of peptides to receptors.82 Thus, the biological activity of Exenatide moiety after 
conjugation with an Fc protein was investigated. Because Exenatide is a GLP-1 agonist, 
the biological activity of Exenatide-Fc was evaluated using the human GLP-1 receptor 
expressed in Xenopus laevis.83 Similar to the pharmacokinetic study, the molar 
concentration of Exenatide-Fc was based on a monomer. As shown in Figure 3.2.1, 
Exenatide and Exenatide-Fc displayed similar GLP-1 activities with EC50 values of 1.1 
and 1.5 nM (as a half-molecule), respectively. These results suggested that Exenatide-Fc 
retained a GLP-1 binding activity comparable to that of the original peptide. As described 
in Chapter 2, this Lys-Fc possesses a spacer of 15 amino acids between the conjugation 
site N-terminal Lys and Fc fragment, to improve enzyme reactivity in the NEXT-A 
reaction. This distance is also expected to minimize inhibition of the binding of the 
conjugated peptide to the GLP-1 receptor.  
 
 
Figure 3.2.1. GLP-1 binding activities of Exenatide and its Fc-fusion in the human GLP-
1 receptor expressed in X. laevis. 
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Exenatide-Fc also displayed potent suppression of blood glucose levels, 
comparable to that of Exenatide in vivo (Figure 3.2.2). The suppressive effect of a single 
administration of Exenatide or Exenatide-Fc on a mouse model of type 2 diabetes, db/db 
mice,84-86 was evaluated. Immediately after administration, the suppression effect of 
blood glucose levels of Exenatide was more rapid than that of Exenatide-Fc (Figure 
3.2.2(B)). This difference in biological responses between Exenatide and Exenatide-Fc 
was presumably due to the difference in absorption rates depending on the sizes of these 
two molecules. However, looking at the area under the curve up to 8 h after administration, 
Exenatide and Exenatide-Fc caused the same degree of suppression of blood glucose 
levels (Figure 3.2.2(C)). Moreover, the results suggest that both the two Exenatide 
moieties in one dimeric Exenatide-Fc fusion molecule had the same pharmacological 
activity as Exenatide peptide alone. Notably, the suppressive effect of Exenatide 
disappeared two days after administration, whereas that of Exenatide-Fc at the same dose 
was retained for three days (Figure 3.2.2(A)). Thus, the area under the curve for Exenatide 
from 0 to 72 h was not significantly different from that of the control group, although that 
for Exenatide-Fc showed a significant difference (p < 0.01 vs. control by Dunnett’s test, 
Figure 3.2.2(C)). This difference indicates that the half-life extension of Exenatide-Fc led 
to a long-acting property.  
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Figure 3.2.2. Pharmacodynamics of Exenatide or Exenatide-Fc in db/db mice. Blood 
glucose concentration over time after a single intraperitoneal administration of Exenatide 
or Exenatide-Fc A) through all experiment periods and B) from 0 to 8 h. Area under the 
curve (AUC) of blood glucose C) from 0 to 8 h and D) from 0 to 72 h. For all experiments, 
the doses were as follows: Exenatide (25.0 nmol/kg), Exenatide-Fc L (3.13 nmol/kg), 
Exenatide-Fc M (12.5 nmol/kg), and Exenatide-Fc H (25.0 nmol/kg). The data are 
presented as mean ± standard error of the mean (n = 4–5 for each group). *p < 0.05 and 
**p < 0.01 vs. control by Dunnett’s test. 
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CHAPTER 4 
 
 
 
Conclusions 
 
 
 
  
 
 
     A general and efficient semi-synthetic method, consisting of the chemoenzymatic 
NEXT-A reaction and SPAAC, to obtain Fc-fusion compounds has been established for 
the first time. This method achieved quantitative bioconjugation between any type of 
pharmacological middle molecule and the N-terminus of an Fc protein. The reactivity of 
the compounds, by modifying the N-terminal azide using the NEXT-A reaction and 
SPAAC of the Fc protein, was improved by optimizing the spacer length between the 
azide group (i.e., peptide attachment site) and the original N-terminus of the highly folded 
Fc protein. Bioconjugation can be performed very efficiently by using a spacer of 15 
amino acid residues, which includes a sequence of the hinge region of natural human 
immunoglobulin G1 antibody. Using this spacer design, the bioconjugation could be 
completed with only 2 molar equivalents of the peptide parts, and synthesis of the peptide-
Fc fusion compound could be carried out at extremely high yields.  
 
In terms of biological activity, both Exenatide and Exenatide-Fc displayed a 
comparable potency. In many cases, bioconjugation of peptides to large molecules, such 
as Fc proteins, decreases the biological activity of peptides. The results of this study 
suggested that the appropriate spacer length between the peptide attachment site at the N-
terminus and the complicatedly folded, large Fc protein not only improved the reactivity 
in the bioconjugation reaction, but also allowed for the biological activity of the 
pharmaceutical peptide to be retained. In addition, the avidity effect due to the dimeric 
structure of the Fc-fusion may also compensate for its biological activity. 
The long half-life of antibodies and Fc-fusion compounds compared to that of small 
molecules is attributed to a combination of two mechanisms: (1) avoidance of renal 
clearance due to large molecular size and (2) recycling via FcRn binding. From this 
viewpoint, the semi-synthesis of Fc-fusion compounds is an appropriate method to impart 
the long half-life of antibodies to artificial Fc-fusion molecules, as the mild reaction 
conditions reduce the risk of impairing the binding affinity to FcRn. Therefore, the Fc-
fusion platform described herein can be universally applied to various kinds of 
pharmaceutical components. 
 
     In current drug discovery, pharmaceutical candidate molecules should be rationally 
designed based on a definite mechanism of action. From this viewpoint, middle molecules 
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such as peptides and oligonucleotides are appropriate compounds for rational molecular 
design. In addition, recent advances in screening technologies such as phage display and 
SELEX make middle molecules much more promising. I believe that the semi-synthetic 
methodology of Fc-fusion described herein will compensate for the major disadvantage 
of middle molecules, the short circulating plasma half-life, and make valuable middle 
molecule pharmaceuticals possible.   
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CHAPTER 5 
 
 
 
Materials and Methods 
 
 
 
  
 
5.1 General Procedures 
 
Leucyl/phenylalanyl-tRNA-protein transferase,87,88 doubly mutated aminoacyl-
tRNA synthetase,54,89 and transfer-RNAPhe54,90 were prepared according to previously 
reported methods. 
Mass spectra were obtained using the 1290 Infinity II LC and 6545XT AdvanceBio 
LC/Q-TOF systems (Agilent Technologies, Inc.) equipped with a PLRP-S column 
(1000A, 5 μm, 2.1 mm I.D. × 50 mm, Agilent Technologies, Inc.). Linear gradient elution 
was performed using 0.1% aqueous formic acid and 0.1% formic acid in acetonitrile as 
the mobile phase. For small molecule materials, mass spectra of ESI-QMS were obtained 
using the 1290 infinity LC and 6130 Quadrupole LC/MS system (Agilent Technologies, 
Inc.) equipped with an Inertsil ODS-3 column (2 μm, 2.1 mm I.D. × 150 mm, GL Science 
Inc.). Nuclear magnetic resonance spectra were obtained using Avance™ III HD NMR 
spectrometer with an Ascend™ 400 magnet (Bruker BioSpin). 
Protein quantification was performed by the direct A280 method based on 
calculated ε values using the Nanodrop 2000 spectrophotometer (Thermo Fisher 
Scientific). SDS-PAGE analysis was performed using the Mini-PROTEAN TGX precast 
protein gel (4–20%, Bio-Rad) with XL-Ladder Broad (APRO Life Science Institute, Inc.) 
as the molecular-weight marker with the use of Bio-safe Coomassie Brilliant Blue G-250 
dye (Bio-Rad) to stain protein samples, unless otherwise specified.  
Analytical size-exclusion chromatograms were obtained using the Superdex 75 
10/300 GL column (10 mm I.D. × 300 mm, GE Healthcare Life Sciences). PBS was used 
as the eluent, and chromatograms were monitored at 280 nm using a UV detector. 
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5.2 Screening of N-Terminal Sequences of Fc Proteins 
 
Preparation of Fc proteins possessing a cysteine residue on its N-terminus (Cys-Fc, 
2). HEK293 cells were transformed with an expression vector obtained by introducing a 
gene encoding the polypeptide consisting of the amino acid sequence of Cys-Fc (Figure 
5.2.1) into pSecTag2/HygroA (Thermo Fisher Scientific) in Opti-MEMI (Thermo Fisher 
Scientific) medium. The obtained transformed cells were cultured by roller culture (125 
rpm) for 5 days under the conditions of 37 ºC and 8% CO2 concentration. The culture 
supernatant was collected by centrifugation and purified by HiTrap Protein A FF (1 mL, 
GE Healthcare) with PBS wash and 0.1 M sodium citrate buffer (pH 2.9) elution, resulting 
in Cys-Fc. The results of SDS-PAGE analyses of obtained Cys-Fc using Mini-PROTEAN 
TGX gels (4-20%, Bio-Rad) under reducing conditions and stained by Bio-safe CBB G-
250 staining (Bio-Rad), are shown in Figure 5.2.2 (A). Obtained Cys-Fc was de-
glycosylated using PNGase F (New England Biolabs) according to the manufacturer’s 
protocol, and analyzed by ESI-TOFMS under reducing conditions. ESI-TOFMS: 
calculated for C1120H1735N295O336S8 24836.9; found, 24834.5 (after deconvolution). Cys-
Fc samples also contained impurities of deficit Fc proteins of Cys or Cys-Pro on their N-
termini (Figure 5.2.2 (B)), and these impurities were removed by cation exchange 
chromatography after native chemical ligation.  
 
 
Figure 5.2.1. Amino acid sequence of Cys-Fc.   
 
1              10                20                30                40
CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
50                60                70                80
VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV
90               100               110                120
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE
130               140               150                160
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG
170               180               190                200
QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC
210                220
SVMHEALHNH YTQKSLSLSP G
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Figure 5.2.2. Analytical results of Cys-Fc. A) SDS-PAGE of obtained Cys-Fc under 
reducing (left) and non-reducing (right) conditions. Lanes 1 and 2 show the molecular-
weight marker and obtained Cys-Fc, respectively. B) ESI-TOFMS spectrum of Cys-Fc 
containing deficit Fc proteins at the N-terminal Cys or Cys-Pro.   
 
General procedure of preparation of peptide linker thioesters. All the peptide linker 
thioesters shown below were prepared by substantially the same method. According to 
solid-phase peptide synthesis using 2-chlorotrityl resin based on the Fmoc method, 
protected peptides possessing the Boc protection on their N-termini were prepared. Then, 
the protected peptides were cleaved with 20% 1,1,1,3,3,3-hexafluoro-2-propanol in 
dichloromethane. The cleaved solutions were concentrated, and resolved with 
dichloromethane. N-Hydroxysuccinimide (10 equiv.), N,N’-diisopropylcarbodiimide (10 
equiv.), thiophenol (30 equiv.), and N,N-diisopropylethylamine (10 equiv.) were added to 
these solutions, and the resulting solutions were stirred for two days at ambient 
temperature. The reaction mixtures were washed with water and concentrated. The 
residues were dissolved in TFA/triisopropylsilane/water (95/2.5/2.5 in volume), and 
stirred for 3 h at ambient temperature. The reaction mixtures were concentrated, and then 
dichloromethane and water were added to the residual mixtures. The aqueous layers were 
purified by preparative HPLC, resulting in the peptide linker thioesters.  
L-Lysyl-L-threonyl-L-histidyl-L-threonine phenylthiol ester, trifluoroacetic acid 
salt (1a, Linker A thioester). 1H NMR (400 MHz, DMSO-d6, δ): 8.93 (br s, 1H, NH), 
8.57 (d, J = 8.8 Hz, 1H, NH), 8.54 (d, J = 8.4 Hz, 1H, NH), 8.36 (d, J = 8.0 Hz, 1H, Ar 
CH), 8.14 (br s, 2H, NH2), 7.79 (br s, 3H, NH2 and NH), 7.48–7.44 (m, 3H, Ar CH), 7.43 
(s, 1H, Ar CH), 7.35–7.31 (m, 2H, Ar CH), 4.93 (dt, J = 8.0 and 6.4 Hz, 1H, CH), 4.46 
(dd, J = 8.4 and 2.8 Hz, 1H, CH), 4.31–4.26 (m, 2H, CH), 3.99–3.89 (m, 2H, CH), 3.32–
3.27 (m, 1H, CH), 3.03 (dd, J = 15.2 and 8.4 Hz, 1H, CH), 2.80–2.71 (m, 2H, CH2), 1.74–
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1.64 (m, 2H, CH2), 1.59–1.49 (m, 2H, CH2), 1.40–1.31 (m, 2H, CH2), 1.08 (t, J = 8.0 Hz, 
6H, CH3). ESI-TOFMS (m/z): [M+H]+ calculated for C26H40N7O6S 578.2760; found, 
578.2765.   
L-Lysyl-L-seryl-L-seryl-L-aspartyl-L-lysyl-L-threonyl-L-histidyl-L-threonine 
phenylthiol ester, trifluoroacetic acid salt (1b, Linker B thioester). 1H NMR (400 MHz, 
DMSO-d6, δ): 8.63 (d, J = 6.4 Hz, 1H, NH), 8.53 (d, J = 8.4 Hz, 1H, NH), 8.29 (d, J = 
7.2 Hz, 1H, Ar CH), 8.14 (br s, 1H, NH), 8.09 (d, J = 7.2 Hz, 2H, NH), 7.94 (d, J = 8.0 
Hz, 1H, NH), 7.93 (br s, 2H, NH), 7.90 (br s, 2H, NH and Ar CH), 7.71 (br s, 6H, NH2), 
7.48–7.40 (m, 3H, Ar CH), 7.35–7.30 (m, 2H, Ar CH), 4.92–4.81 (m, 1H, CH), 4.59 (q, 
J = 7.2 Hz, 1H, CH), 4.51–4.41 (m, 2H, CH), 4.40–4.23 (m, 3H, CH), 4.20–4.13 (m, 1H, 
CH), 3.97–3.89 (m, 1H, CH), 3.85 (t, J = 4.0 Hz, 1H, CH), 3.67–3.54 (m, 4H, CH2), 3.07–
2.93 (m, 2H, CH2), 2.80–2.66 (m, 6H, CH2), 1.76–1.65 (m, 4H, CH2), 1.58–1.42 (m, 4H, 
CH2), 1.41–1.22 (m, 4H, CH2), 1.07 (d, J = 6.0 Hz, 3H, CH3), 1.02 (d, J = 6.4 Hz, 3H, 
CH3). ESI-TOFMS (m/z): [M+H]+ calculated for C42H67N12O14S 995.4620; found, 
995.4953.   
L-Lysyl-L-valyl-L-glutamyl-L-prolyl-L-lysyl-L-seryl-L-seryl-L-aspartyl-L-lysyl-L-
threonyl-L-histidyl-L-threonine phenylthiol ester, trifluoroacetic acid salt (1c, 
Linker C thioester). 1H NMR (400 MHz, DMSO-d6, δ): 8.53 (d, J = 8.0 Hz, 1H, NH), 
8.40 (d, J = 8.4 Hz, 1H, NH), 8.29 (d, J = 6.4 Hz, 2H, NH), 8.23–8.03 (m, 4H, NH and 
Ar CH), 7.97 (t, J = 8.0 Hz, 2H, NH), 7.92–7.64 (m, 10H, NH2, NH and Ar CH), 7.48–
7.43 (m, 3H, Ar CH), 7.36–7.29 (m, 2H, Ar CH), 5.20–5.06 (m, 1H, CH), 4.95–4.86 (m, 
1H, CH), 4.67–4.56 (m, 1H, CH), 4.56–4.40 (m, 2H, CH), 4.40–4.12 (m, 7H, CH), 3.99–
3.90 (m, 1H, CH), 3.86 (br s, 1H, CH), 3.70–3.51 (m, 8H, CH2), 3.08–2.93 (m, 2H, CH2), 
2.82–2.65 (m, 8H, CH2), 2.37–2.29 (m, 2H, CH2), 2.10–1.98 (m, 1H, CH), 1.98–1.77 (m, 
4H, CH2), 1.77–1.61 (m, 4H, CH2), 1.61–1.42 (m, 8H, CH2), 1.42–1.21 (m, 6H, CH2), 
1.07 (d, J = 6.4 Hz, 3H, CH3), 1.03 (d, J = 6.0 Hz, 3H, CH3), 0.87 (d, J = 5.2 Hz, 3H, 
CH3), 0.85 (d, J = 6.8 Hz, 3H, CH3). ESI-TOFMS (m/z): [M+H]+ calculated for 
C63H102N17O20S 1448.7208; found, 1448.7505.   
L-Lysyl-L-lysyl-L-valyl-L-glutamyl-L-prolyl-L-lysyl-L-seryl-L-seryl-L-aspartyl-L-
lysyl-L-threonyl-L-histidyl-L-threonine phenylthiol ester, trifluoroacetic acid salt 
(1d, Linker D thioester). 1H NMR (400 MHz, DMSO-d6, δ): 8.57 (d, J = 8.0 Hz, 1H, 
NH), 8.52 (d, J = 8.0 Hz, 1H, NH), 8.34–8.24 (m, 2H, NH), 8.23–8.10 (m, 3H, NH), 8.10–
8.03 (m, 2H, NH and Ar CH), 8.02–7.62 (m, 16H, NH2, NH and Ar CH), 7.47–7.43 (m, 
3H, Ar CH), 7.38–7.31 (m, 2H, Ar CH), 4.92–4.83 (m, 1H, CH), 4.65–4.54 (m, 1H, CH), 
4.54–4.08 (m, 11H, CH), 3.99–3.83 (m, 1H, CH), 3.83–3.73 (m, 1H, CH), 3.73–3.48 (m, 
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8H, CH2), 3.04–2.88 (m, 2H, CH2), 2.85–2.62 (m, 10H, CH2), 2.37–2.26 (m, 2H, CH2), 
2.10–1.98 (m, 1H, CH), 1.98–1.79 (m, 4H, CH2), 1.79–1.60 (m, 6H, CH2), 1.60–1.42 (m, 
10H, CH2), 1.42–1.21 (m, 8H, CH2), 1.07 (d, J = 6.4 Hz, 3H, CH3), 1.02 (d, J = 6.4 Hz, 
3H, CH3), 0.81 (d, J = 6.8 Hz, 3H, CH3), 0.80 (d, J = 6.4 Hz, 3H, CH3). ESI-TOFMS 
(m/z): [M+H]+ calculated for C69H114N19O21S 1576.8157; found, 1576.8375.   
L-Lysyl-L-valyl-L-aspartyl-L-lysyl-L-lysyl-L-valyl-L-glutamyl-L-prolyl-L-lysyl-L-
seryl-L-seryl-L-aspartyl-L-lysyl-L-threonyl-L-histidyl-L-threonine phenylthiol 
ester, trifluoroacetic acid salt (1e, Linker E thioester). 1H NMR (400 MHz, DMSO-d6, 
δ): 8.51–8.39 (m, 1H, NH), 8.39–8.27 (m, 1H, NH), 8.27–8.16 (m, 1H, NH), 8.16–7.50 
(m, 21H, NH2, NH and Ar CH), 7.50–7.39 (m, 3H, Ar CH), 7.39–7.32 (m, 2H, Ar CH), 
4.79–4.68 (m, 1H, CH), 4.61–4.38 (m, 4H, CH), 4.38–4.06 (m, 11H, CH), 3.99–3.88 (m, 
1H, CH), 3.88–3.80 (m, 1H, CH), 3.80–3.50 (m, 8H, CH2), 2.98–2.85 (m, 2H, CH2), 2.85–
2.58 (m, 14H, CH2), 2.36–2.23 (m, 2H, CH2), 2.12–2.00 (m, 1H, CH), 2.00–1.78 (m, 6H, 
CH2), 1.78–1.62 (m, 6H, CH2), 1.62–1.41 (m, 12H, CH2), 1.41–1.22 (m, 10H, CH2), 1.09 
(d, J = 6.4 Hz, 3H, CH3), 0.99 (d, J = 6.0 Hz, 3H, CH3), 0.87 (d, J = 8.0 Hz, 3H, CH3), 
0.86 (d, J = 7.2 Hz, 3H, CH3), 0.81 (d, J = 6.4 Hz, 3H, CH3), 0.80 (d, J = 6.4 Hz, 3H, 
CH3). ESI-TOFMS (m/z): [M+H]+ calculated for C84H140N23O26S 1919.0061; found, 
1919.0114.   
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Figure 5.2.3. 1H-NMR spectra of peptide linker thioesters. (A) Linker A thioester. (B) 
Linker B thioester. (C) Linker C thioester. (D) Linker D thioester. (E) Linker E thioester.  
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Figure 5.2.3. (continued) 
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Figure 5.2.3. (continued) 
 
General procedure of preparation of Fc proteins possessing a lysine residue on their 
N-termini (3). The Fc proteins with N-terminal lysine were prepared according to the 
literature.41,91 For more detail, Cys-Fc was diluted to the concentration of 0.02 mM into 
50 mM MES buffer (pH 6.5) containing 1.0 mM tris(2-carboxyethyl)phosphine (TCEP) 
and 10 mM 4-mercaptophenylacetic acid (MPAA). To this solution, peptide linker 
thioester (Linker A–E) was dissolved in the concentration of 0.4 mM, and mixed 
overnight at 25 ºC. The reaction solution was replaced with 20 mM ammonium acetate 
buffer (pH 5.5) using Vivaspin 500 (10k MWCO, Sartorius), and then purified with 
Resource S (1 mL, GE Healthcare) in a linear gradient from 20 mM sodium acetate (pH 
5.5) to 50 mM MES buffer containing 0.5 M sodium chloride (pH 6.5).  
Linker A-Fc (3a). ESI-TOFMS: Calculated for C1190H1848N304O380S8 26749.7 (with G0F 
glycoform) and C1196H1858N304O385S8 26911.9 (with G1F glycoform); found, 26746.8 and 
26908.9 (after deconvolution). 
Linker B-Fc (3b). ESI-TOFMS: Calculated for C1206H1875N309O388S8 27167.1 (with G0F 
glycoform) and C1212H1885N309O393S8 27329.3 (with G1F glycoform); found, 27164.7 and 
27326.9 (after deconvolution). 
Linker C-Fc (3c). ESI-TOFMS: Calculated for C1227H1910N314O394S8 27620.7 (with G0F 
glycoform) and C1233H1920N314O399S8 27782.8 (with G1F glycoform); found, 27617.6 and 
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27779.6 (after deconvolution). 
Linker D-Fc (3d). ESI-TOFMS: Calculated for C1233H1922N316O395S8 27748.9 (with G0F 
glycoform) and C1239H1932N316O400S8 27911.0 (with G1F glycoform); found, 27745.6 and 
27908.3 (after deconvolution). 
Linker E-Fc (3e). ESI-TOFMS: Calculated for C1248H1948N320O400S8 28091.2 (with G0F 
glycoform) and C1254H1958N320O405S8 28253.4 (with G1F glycoform); found, 28087.9 and 
28250.1 (after deconvolution). 
 
 
Figure 5.2.4. SDS-PAGE of purified Lys-Fc proteins with different N-terminal chain 
lengths under reducing conditions. (A) Linker A-Fc. (B) Linker B-Fc. (C) Linker C-Fc. 
(D) Linker D-Fc. (E) Linker E-Fc. Lanes 1, 2 and 3 show molecular-weight marker, Cys-
Fc and Lys-Fc, respectively.   
 
Preparation of PEG-DIBAC. To a solution of 5-(5,6-dihydro-11,12-
didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoic acid (DIBAC acid, 16.1 mg, 
50.4 μmol)92,93 in dichloromethane (1 mL), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC-HCl, 14.7 mg, 76.7 μmol), 1-
hydroxybenzotriazole monohydrate (HOBt-H2O, 11.7 mg, 76.4 μmol), and 
diisopropylethylamine (DIPEA, 17.5 μL, 100 μmol) were added. Methoxypolyethylene 
glycol propylamine (SUNBRIGHT MEPA-20H, 102.2 mg, 51.1 μmol) was added to this 
solution, and mixed overnight at ambient temperature. The reaction mixture was then 
washed with saturated aqueous ammonium chloride and brine, and concentrated in vacuo. 
The residue was purified with silica gel column chromatography (dichloromethane ~ 
dichloromethane/methanol = 10/1), resulting in PEG-DIBAC (94 mg, 41 μmol). 1H NMR 
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(400 MHz, DMSO-d6, δ): 7.70 (d, J = 7.2 Hz, 1H, Ar CH), 7.43–7.29 (m, 7H, Ar CH), 
5.98 (br s, 1H, NH), 5.15 (d, J = 14.0 Hz, 1H, one of CH2), 3.85–3.79 (m, 1H, CH2), 3.71–
3.58 (m, 171 H, CH2), 3.58–3.53 (m, 6H, CH2), 3.50–3.45 (m, 4H, CH2), 3.38 (s, 3H, 
CH3), 3.31–3.35 (m, 2H, CH2), 2.32–2.23 (m, 1H, CH2), 1.97–1.83 (m, 4H, CH2), 1.74–
1.64 (m, 4H, CH2).   
 
 
Figure 5.2.5. Chemical structure of PEG-DIBAC.   
 
 
 
 
Figure 5.2.6. 1H-NMR spectrum of PEG-DIBAC.   
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Figure 5.2.7. ESI-TOFMS spectrum of PEG-DIBAC.   
 
General procedure of the evaluation of the reactivities of Fc proteins possessing 
different N-terminal sequences on the NEXT-A reaction and following the SPAAC 
reaction. To a reaction tube, 4.0 μL of stock solution A (100 mM MgCl2, 10 mM 
spermidine, in 500 mM HEPES buffer, pH 7.6) and 4.0 μL of stock solution B (25 mM 
adenosine triphosphate and 200 mM potassium chloride in water) were added, and then 
2.0 μL of tRNAPhe solution (0.10 O.D./μL), 4.5 μL of double-mutant aminoacyl-tRNA 
synthetase solution (17.8 μmol/L), 2.1 μL of leucyl/phenylalanyl-tRNA-protein 
transferase solution (39 μmol/L), 14.5 μL of 1 mM 4-azidophenylalanine solution, and 
3.4 μL of water were added. To this solution, Fc protein with N-terminal lysine (5.5 μL, 
in the concentration of 1.2 to 2.3 mg/mL in PBS) was added, and mixed for 5 h at 37 ºC. 
Then, 2 mM PEG-DIBAC in DMSO (30 μL) was added to the reaction mixture, and 
additionally mixed overnight at 25 ºC. The reaction mixture was purified with Aspire 
Protein A Tips (Thermo Fisher Scientific) according to the manufacturer’s protocol, and 
the ratio of the PEG-adduct and unreacted Fc protein was evaluated by SDS-PAGE 
analysis (Mini-PROTEAN TGX gel, 4 to 20%, Bio-Rad, stained by SYPRO Ruby®, 
Thermo Fisher Scientific) in reducing conditions. The data are shown in Figure 2.2.2. The 
ratios between adducts and unreacted Fc proteins with N-terminal lysine were calculated 
based on the fluorescent intensities measured using an Amersham Imager 600 (GE 
Healthcare). 
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5.3 Screening of Bioconjugation Reactions 
 
Materials. O-Propargyltyrosine was purchased from IRIS, and 4-(azido)phenylalanine 
was purchased from Bachem. Exenatide-Cys-NH2 was prepared by solid-phase peptide 
synthesis using the Rink Amide-ChemMatrix® resin (0.263 mmol scale, Matrix 
Innovation, Inc.) according to the general Fmoc method.94  
 
Preparation of 4-(Chloroacetamide)phenylalanine. To a solution of 4-amino-N-(tert-
butoxycarbonyl)-L-phenylalanine (1.01 g, 3.61 mmol) in dichloromethane (10 mL) and 
DMF (1 mL), chloroacetyl chloride (0.30 mL, 3.75 mmol) and triethylamine (0.60 mL, 
4.28 mmol) were added, and stirred for 0.5 h at ambient temperature. The pH of the 
reaction mixture was adjusted to 3 by the addition of 0.01 M hydrochloride, and the 
organic layer was collected, dried with sodium sulfate, and evaporated. The residue was 
purified with silica gel column chromatography (dichloromethane:methanol = 30:1), 
resulting in 4-(chloroacetamide)-N-(tert-butoxycarbonyl)-L-phenylalanine (1.18 g, 3.31 
mmol, 92% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6, ): 10.23 (s, 1H, NH), 
7.48 (d, 2H, J = 8.4 Hz, Ar CH), 7.19 (d, 2H, J = 8.4 Hz, Ar CH), 7.07 (d, 1H, J = 8.4 Hz, 
CH), 4.23 (s, 2H, COCH2Cl), 2.99–2.94 and 2.78–2.73 (each 1H, m, CH2), 1.32 (s, 9H, 
CH3). 4-(Chloroacetamide)-N-(tert-butoxycarbonyl)-L-phenylalanine (25.0 mg, 70.1 
mol) was added to trifluoroacetic acid (500 L), and stirred for 0.5 h at ambient 
temperature. The reaction mixture was evaporated, diluted with water, and lyophilized, 
resulting in 4-(chloroacetamide)phenylalanine trifluoroacetic acid salt (14.3 mg, 38.6 
mol, 55%) as a white powder. 1H NMR (400 MHz, DMSO-d6, ): 10.26 (s, 1H, NH), 
8.13 (br s, 2H, NH2), 7.47 (d, 2H, J = 8.8 Hz, Ar CH), 7.14 (d, 2H, J = 8.4 Hz, Ar CH), 
4.18 (s, 2H, COCH2Cl), 4.07 (t, 1H, J = 6.4 Hz, CH), 3.01–2.93 (2H, m, CH2). ESI-QMS 
(m/z): [M+H]+ calculated for C11H14ClN2O3 257.1 and 259.1; found, 257.0 and 259.0.  
 
Preparation of 4-(Bromoacetamide)phenylalanine. To a solution of bromoacetic acid 
(0.13 g, 0.94 mmol) in THF (2 mL), N,N’-dicyclohexylcarbodiimide (0.10 g, 0.48 mmol) 
was added and stirred for 2.5 h at ambient temperature. The reaction mixture was filtered, 
and 4-amino-N-(tert-butoxycarbonyl)-L-phenylalanine (0.10 g, 0.36 mmol) was added to 
the filtrate, and stirred for a further 19 h at ambient temperature. The reaction mixture 
was purified by silica gel column chromatography (dichloromethane:methanol = 40:1), 
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resulting in 4-(bromoacetamide)-N-(tert-butoxycarbonyl)-L-phenylalanine (60 mg, 0.15 
mmol, 42% yield) as a solid. 1H NMR (400 MHz, CDCl3, ): 8.29 (br s, 1H, NH), 7.49 
(d, 2H, J = 8.4 Hz, Ar CH), 7.14 (d, 2H, J = 8.4 Hz, Ar CH), 4.97 (d, 1H, J = 6.4 Hz, CH), 
4.58 (d, 1H, J = 5.6 Hz, CH), 4.03 (s, 2H, COCH2Br), 3.13–3.12 (2H, m, CH2), 1.44 (s, 
9H, CH3). 4-(Bromoacetamide)-N-(tert-butoxycarbonyl)-L-phenylalanine (60.0 mg, 0.15 
mmol) was added to trifluoroacetic acid (1.0 mL), and stirred for 0.5 h at ambient 
temperature. The reaction mixture was evaporated, and dried, resulting in 4-
(bromoacetamide)phenylalanine trifluoroacetic acid salt (55.0 mg, 0.13 mmol, 87% 
yield) as a white solid. 1H NMR (400 MHz, DMSO-d6, ): 10.41 (s, 1H, NH), 8.21 (br s, 
3H, NH3), 7.54 (d, 2H, J = 8.4 Hz, Ar CH), 7.21 (d, 2H, J = 8.8 Hz, Ar CH), 4.16 (br s, 
1H, CH), 4.03 (s, 2H, COCH2Br), 3.06–3.04 (2H, m, CH2). ESI-QMS (m/z): [M+H]+ 
calculated for C11H14BrN2O3 301.0 and 303.0; found, 300.9 and 303.0.  
 
Preparation of 4-(Iodoacetamide)phenylalanine. To a solution of iodoacetic acid (3.31 
g, 17.8 mmol) in THF (20 mL), N,N’-dicyclohexylcarbodiimide (1.92 g, 9.31 mmol) was 
added and stirred for 0.5 h at ambient temperature. The reaction mixture was filtered, and 
4-amino-N-(tert-butoxycarbonyl)-L-phenylalanine (2.06 g, 7.36 mmol) was added to the 
filtrate, and stirred for a further 19 h at ambient temperature. The reaction mixture was 
purified by silica gel column chromatography (dichloromethane:methanol = 50:1), 
resulting in 4-(iodoacetamide)-N-(tert-butoxycarbonyl)-L-phenylalanine (3.06 g, 7.13 
mmol, 96% yield) as a solid. 1H NMR (400 MHz, CDCl3, ): 7.49 (d, 2H, J = 8.0 Hz, Ar 
CH), 7.10 (d, 2H, J = 8.0 Hz, Ar CH), 5.02 (d, 1H, J = 8.0 Hz, NH), 4.61 (d, 1H, J = 7.2 
Hz, CH), 3.91 (s, 2H, COCH2I), 3.13 (2H, m, CH2), 1.45 (s, 9H, CH3). 4-(Iodoacetamide)-
N-(tert-butoxycarbonyl)-L-phenylalanine (3.06 g, 6.83 mmol) was added to 
trifluoroacetic acid (15.0 mL), and stirred for 0.5 h at ambient temperature. The reaction 
mixture was evaporated, diluted with water, and lyophilized, resulting in 4-
(iodoacetamide)phenylalanine trifluoroacetic acid salt (2.74 g, 5.93 mmol, 87% yield) as 
a white solid. 1H NMR (400 MHz, DMSO-d6, ): 10.38 (s, 1H, NH), 8.24 (br s, 2H, NH2), 
7.52 (d, 2H, J = 8.8 Hz, Ar CH), 7.20 (d, 2H, J = 8.4 Hz, Ar CH), 4.15 (t, 1H, J = 6.4 Hz, 
CH), 3.82 (s, 2H, COCH2Br), 3.06–3.04 (2H, m, CH2). ESI-QMS (m/z): [M+H]+ 
calculated for C11H14IN2O3 349.0; found, 348.6. 
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Preparation of PEG-alkyne. To a solution of 2,2-dimethyl-4-oxo-3,8,11,14,17,20,23, 
26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98,101,104,1
07,110,113-heptatriacontaoxa-5-azahexadecahectan-116-oic acid (t-Boc-N-amido-
dPEG36-acid, 51.3 mg, 28.9 μmol) in dichloromethane (1 mL), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl, 7.1 mg, 37.0 
μmol), 1-hydroxybenzotriazole monohydrate (HOBt-H2O, 5.8 mg, 37.9 μmol), and 
diisopropylethylamine (DIPEA, 7.2 μL, 42.3 μmol) were added. Propargylamine (1.8 μL, 
28.1 μmol) was added to this solution, and mixed overnight at ambient temperature. The 
reaction mixture was then washed with water (1 mL), dried with sodium sulfate, and 
evaporated. The residue was purified with silica gel column chromatography 
(dichloromethane/methanol = 10/1 to 5/1), resulting in t-Boc-N-amido-dPEG36 
propargylamide (33 mg, 18.2 μmol, 63% yield). To t-Boc-N-amido-dPEG36 
propargylamide (31 mg, 17.1 μmol), 4 M HCl in ethyl acetate (1 mL) was added and 
stirred for 0.5 h at ambient temperature. The reaction mixture was evaporated, and then 
the residue was dissolved in water and lyophilized, resulting in PEG-alkyne (33 mg). 1H 
NMR (400 MHz, DMSO-d6, δ):  8.28 (t, J = 4.8 Hz, 1H, NH), 3.85 (dd, J = 5.6 and 2.4 
Hz, 2H, propargyl CH2), 3.64–3.42 (m, 150H, PEG CH2), 3.09 (t, J = 2.4 Hz , 1H, 
propargyl CH), 3.20–2.93 (m, 2H, H2NCH2). ESI-QMS (m/z): calculated for 
C78H154N2O37 1711.0; found, 856.3 ([M+2H]2+) and 571.5 ([M+3H]3+).  
 
 
Figure 5.3.1. Synthetic route of PEG-alkyne.   
 
 
Procedure of Cu-mediated azide-alkyne cyclization to Fc protein. To a solution of N3-
Fc (10 μL, 0.20 mg/mL), 10 mM PEG-alkyne solution (1.3 μL), reagent mixture 1 (1.0 
μL of aqueous 13 mM copper(II) sulfate, 67 mM tris(3-hydroxypropyltriazolylmethyl)-
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amine95-97 solution), and reagent mixture 2 (1.0 μL of 67 mM aminoguanidine 
hydrochloride, 67 mM sodium ascorbate in 0.1 M sodium phosphate buffer, pH 7.0) were 
added and shaken overnight at 25 ºC. The reaction mixture was analyzed by SDS-PAGE 
(Mini-PROTEAN TGX gel, 4 to 20%, Bio-Rad, stained by SYPRO Ruby®, Thermo 
Fisher Scientific) in reducing conditions. The ratios between PEG-adduct and unreacted 
Fc proteins were calculated based on the fluorescent intensities measured using an 
Amersham Imager 600 (GE Healthcare). 
 
 
Figure 5.3.2. SDS-PAGE of the reaction mixture of the CuAAC reaction in reducing 
conditions. Lanes 1, 2 and 3 show molecular-weight marker, N3-Fc and the CuAAC 
reaction mixture, respectively.   
 
General procedure of S-alkylation reactions to the Fc protein. Investigations on S-
alkylation using Fc proteins with chloro-, bromo-, and iodo-acetyl groups were performed 
in the following manner. To a reaction tube, 8.0 μL of stock solution A (100 mM MgCl2, 
10 mM spermidine, in 500 mM HEPES buffer, pH 7.6) and 8.0 μL of stock solution B 
(25 mM adenosine triphosphate and 200 mM potassium chloride in water) were added, 
and then 4 μL of tRNAPhe solution (0.10 O.D./μL), 9.0 μL of double-mutant aminoacyl-
tRNA synthetase solution (17.8 μmol/L), 4.1 μL of leucyl/phenylalanyl-tRNA-protein 
transferase solution (39 μmol/L), 29 μL of 11 mM 4-(chloroacetamide)phenylalanine 
solution, and 9.5 μL of water were added. To this solution, Fc protein with N-terminal 
lysine (5.5 μL, 2.5 mg/mL in PBS) was added, and mixed for 5 h at 37 ºC. The reaction 
mixture was purified with Aspire Protein A Tips (Thermo Fisher Scientific) according to 
the manufacturer’s protocol, and buffer of the effluent was exchanged to 0.1 M HEPES 
buffer (pH 7.5) using a Vivaspin 500 (10k MWCO, Sartorius) and concentrated to 25 μL. 
To the resultant solution, 5 μL of aqueous Exenatide-Cys solution (18 mM) was added, 
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and mixed for 4 days at 25 ºC. The reaction mixture was analyzed by SDS-PAGE (Mini-
PROTEAN TGX gel, 4 to 20%, Bio-Rad, stained by SYPRO Ruby®, Thermo Fisher 
Scientific) in reducing conditions. The ratios between peptide-adducts and unreacted Fc 
proteins were calculated based on the fluorescent intensities measured using an 
Amersham Imager 600 (GE Healthcare). 
 
 
Figure 5.3.3. SDS-PAGE of the reaction mixture of S-alkylation with Fc proteins in 
reducing conditions. Lanes 1, 2, 3, 4 and 5 show molecular-weight marker, Lys-Fc, and 
reaction mixtures of S-alkylation (from left to right, using chloro-, bromo-, and iodo-
incorporated phenylalanine derivatives), respectively.   
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5.4 Semi-syntheses of Peptide-Fc Fusion Compounds 
 
Expression of Lys-Fc. Expi293F cells (Thermo Fisher Scientific) were grown in serum-
free Expi293F™ expression medium (Thermo Fisher Scientific) with 8% CO2 at 37 C. 
The recombinant plasmid encoding Lys-Fc (Figure 5.4.1) was inserted into the pcDNA™ 
3.4 TOPO® vector (Thermo Fisher Scientific) and transiently transfected into a 4-L 
suspension of the Expi293F cell culture. After six days of incubation, the cell culture 
supernatant was centrifuged at 6000 rpm for 25 min using the GL-10MD centrifuge 
(Hunan Xiangyi Laboratory Instrument Development Co., Ltd.) and then filtered. The 
filtered cell culture supernatant was adjusted to pH 7.20–7.40 with 1 M Tris-HCl (pH 9.0) 
and purified by a Monofinity A Resin prepacked column (5 mL, GenScript). The purified 
fraction was immediately neutralized with 1 M Tris-HCl (pH 9.0), and the buffer was 
exchanged with HyClone PBS solution (pH 7.2, Thermo Fisher Scientific) using the 
HiPrep 26/10 desalting column (GE Healthcare Life Sciences) to generate 30 mL of Lys-
Fc solution in PBS. The concentration of Lys-Fc, determined by the Bradford assay with 
BSA as the standard, was 8.80 mg/mL. Lys-Fc was analyzed by ESI-TOFMS under 
reducing condition. ESI-TOFMS: Calculated for C1248H1948N320O400S8 28091.2 (with G0F 
glycan) and C1254H1958N320O405S8 28253.4 (with G1F glycan); found, 28088.5 and 
28250.5 (after deconvolution). 
 
 
 
 
 
 
 
 
 
 
 
74
 
 
DNA sequence: 795 bp 
GAATTCCCGCCGCCACCATGGGCTGGTCCTGCATCATTCTGTTTCTGGTGGCC
ACAGCCACCGGCGTGCACTCTAAGGTGGACAAGAAGGTGGAACCCAAGAGC
AGCGACAAGACCCACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCG
GACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATGATCAGC
AGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGATCCC
GAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAG
ACCAAGCCTAGAGAGGAACAGTACAACAGCACCTACAGAGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG
GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAAACCATCAGCAAGGCCA
AGGGCCAGCCTAGGGAACCCCAGGTTTACACACTGCCTCCAAGCAGGGACG
AGCTGACCAAGAATCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCC
TTCCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACTAC
AAGACAACCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAGCA
AGCTGACAGTGGACAAGTCCAGATGGCAGCAGGGCAACGTGTTCAGCTGCA
GCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCC
TGTCTCCTGGATGATAAGCTT 
(EcoRI--Kozak sequence--Artificial signal peptide--hIgG1 Fc (93-329, C103S)--Stop 
codon—HindIII) 
Figure 5.4.1. DNA sequence of the Fc protein possessing a lysine residue on its N-
terminus.  
 
Preparation of N3-Fc. The following were added to a reaction vessel (Celstar® spinner 
flask, 25 mL): 1.07 mL of stock solution A (100 mM MgCl2 and 10 mM spermidine in 
500 mM HEPES buffer, pH 7.6) and 1.07 mL of stock solution B (25 mM adenosine 
triphosphate and 200 mM KCl in water). Subsequently, 547 μL of tRNAPhe solution 
(0.195 O.D./μL), 2.40 mL of doubly mutated aminoacyl-tRNA synthetase solution (17.8 
μmol/L), 1.09 mL of leucyl/phenylalanyl-tRNA-protein transferase solution (39.0 
μmol/L), 1.71 mL of 25.0 mM 4-azidophenylalanine solution, and 1.50 mL of water were 
added. Lys-Fc (1.29 mL, 15.5 mg/mL in PBS) was then added, and the solution was mixed 
for 23 h at 37 C. The reaction mixture was purified by the HiTrap rProtein A FF column 
(1 mL, GE Healthcare Life Sciences) using PBS for capture and 0.10 M citric acid buffer 
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(pH 2.7) for elution, and the fraction was neutralized with 1.0 M Tris (pH 9.0). 
Subsequently, the buffer was exchanged with 0.10 M sodium phosphate buffer (pH 7.0) 
using an Amicon Ultra-4 centrifugal filter unit (10K MWCO, Merck Millipore) to 
generate 1.50 mL of N3-Fc solution (12.5 mg/mL, 93% yield). N3-Fc was analyzed by 
ESI-TOFMS under reducing conditions. ESI-TOFMS: Calculated for 
C1257H1956N324O401S8 28279.4 (with G0F glycan) and C1263H1966N324O406S8 28441.6 (with 
G1F glycan); found, 28273.7 and 28435.7 (after deconvolution). 
 
Preparation of Exenatide-DBCO (4). Exenatide-Cys-NH2 was prepared by solid-phase 
peptide synthesis using the Rink Amide-ChemMatrix® resin (0.263 mmol scale, Matrix 
Innovation, Inc.) according to the general Fmoc method94 and cleaved from the resin 
using TFA/triisopropylsilane/water (95:2.5:2.5, v/v/v). The resulting solution was added 
to cold diethylether, and the precipitate was washed five times with the same solvent. The 
precipitate was air-dried and purified by preparative HPLC to yield a 5 TFA salt of the 
Exenatide-Cys-NH2 peptide (39.5 mg, 3.1% yield). Next, 264 μL of DBCO-maleimide 
(40 mM in DMSO, 10.6 μmol, Tokyo Chemical Industry) were added to 3.26 mL of 
Exenatide-Cys-NH2 (30.2 mg, 6.21 μmol) solution in 0.1 M sodium phosphate buffer (pH 
7.0), and then mixed for 5 h at 25 C. The buffer of the reaction mixture was exchanged 
with water by repeated ultrafiltration with an Amicon Ultra-4 centrifugal filter unit (3K 
MWCO), followed by dilution with water. The resulting solution was freeze-dried to 
produce Exenatide-DBCO (21.4 mg, 4.05 μmol, 65% yield). ESI-TOFMS (m/z): 
Calculated for C212H308N54O65S2 4714.1897; found, 2358.0981 ([M+2H]2+), 1572.4046 
([M+3H]3+). 
 
Preparation of Exenatide-Fc. An N3-Fc solution (645 μL, 12.5 mg/mL, 0.300 μmol as 
a half-molecule) was supplemented with 0.1 M sodium phosphate buffer (pH 7.0, 5.24 
mL) and 5.0 mM Exenatide-DBCO solution (299 μL, 1.50 μmol), and then shaken 
overnight at ambient temperature. The reaction mixture was directly purified by passing 
through the HiLoad 16/600 Superdex 75 pg prepacked column (GE Healthcare Life 
Sciences) and concentrated using an Amicon Ultra-15 centrifugal filter unit (10K 
MWCO) to produce an Exenatide-Fc solution in PBS (4.0 mL, 2.06 mg/mL, 87% yield). 
Exenatide-Fc was analyzed by ESI-TOFMS under reducing conditions. ESI-TOFMS: 
Calculated for C1469H2264N378O466S10 32996.60 (with G0F glycoform) and 
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C1475H2274N378O471S10 33158.74 (with G1F glycoform); found, 32996.3 and 33157.4 
(after deconvolution). 
 
Preparation of abarelix-DBCO (5). Abarelix-Cys-NH2 peptide was purchased from 
Toray Research Center, Inc. To 576 μL of aqueous solution of Abarelix-Cys-NH2 (11.5 
mg, 6.18 μmol, calculated as 2 TFA salt), 26.4 μL of dibenzocyclooctyne-maleimide 
solution (DBCO-maleimide, Tokyo Chemical Industries, 400 mM in DMSO, 10.6 μmol) 
and DMSO (166 μL) were added and mixed overnight at ambient temperature. The 
reaction mixture was purified with preparative HPLC (Inertsil ODS-3, 20 I.D. x 200 mm, 
linear gradient with 100 mM ammonium acetate and acetonitrile), and freeze-dried, 
resulting in Abarelix-DBCO (4.5 mg, 2.0 μmol, 32% yield). ESI-TOFMS (m/z): [M+H]+ 
calculated for C104H128ClN20O21S 2059.89; found, 2059.94.   
 
Cyclic RGD peptide-DBCO (6). Cyclic RGD peptide-Cys-NH2 peptide was purchased 
from Toray Research Center, Inc. To 663 μL of aqueous solution of cyclic RGD peptide-
Cys-NH2 (13.3 mg, 14.2 μmol, calculated as 2 TFA salt), 70.4 μL of dibenzocyclooctyne-
maleimide (DBCO-maleimide, Tokyo Chemical Industries, 400 mM in DMSO, 28.2 
μmol) and DMSO (151 μL) were added and mixed overnight at ambient temperature. The 
reaction mixture was purified with preparative HPLC (Inertsil ODS-3, 20 I.D. x 200 mm, 
linear gradient with 100 mM ammonium acetate and acetonitrile), and freeze-dried, 
resulting in cyclic RGD peptide-DBCO (9.8 mg, 7.2 μmol, 51% yield). ESI-TOFMS 
(m/z): [M+H]+ calculated for C55H68N13O12S 1134.48; found, 1134.49.   
 
 
Abarelix-Fc. To a solution of N3-Fc (6.6 μL, 7.58 mg/mL, 50 μg), 0.1 M sodium 
phosphate buffer (pH 7.0, 4.8 μL), water (20 μL) and 2.5 mM aqueous Abarelix-DBCO 
solution (7.4 μL, 18.5 nmol) were added and shaken overnight at 25 ºC, resulting in 
Abarelix-Fc. The reaction mixture was analyzed by SDS-PAGE (Mini-PROTEAN TGX 
gel, 4 to 20%, Bio-Rad, stained by Coomassie Brilliant Blue G-250, Bio-Rad) in reducing 
conditions (Figure 2.4.3), and the band shift corresponding to the increase in molecular 
weight by conjugation was observed. The reaction mixture was purified with Aspire 
Protein A Tips (Thermo Fisher Scientific) according to the manufacturer’s protocol, and 
the eluent was analyzed by ESI-TOFMS. ESI-TOFMS, in reducing conditions: 
Calculated for C1361H2083ClN344O422S9 (with G0 glycan) 30340.2; found, 30339.5 (after 
deconvolution).   
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Cyclic RGD peptide-Fc. N3-Fc (50 μg) was conjugated with cyclic RGD peptide-DBCO 
(18.5 nmol) in a similar manner, resulting in cyclic RGD peptide-Fc. The reaction mixture 
was analyzed by SDS-PAGE (Mini-PROTEAN TGX gel, 4 to 20%, Bio-Rad, stained by 
Coomassie Brilliant Blue G-250, Bio-Rad) in reducing conditions (Figure 2.4.3), and the 
band shift corresponding to an increase in molecular weight by conjugation was observed. 
The reaction mixture was purified with Aspire Protein A Tips (Thermo Fisher Scientific) 
according to the manufacturer’s protocol, and the eluent was analyzed by ESI-TOFMS. 
ESI-TOFMS, in reducing conditions: Calculated for C1312H2023N337O413S9 (with G0 
glycan) 29413.7; found, 29412.5 (after deconvolution).   
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5.5 Semi-syntheses of DNA Aptamer-Fc Fusion Compounds 
 
 
Figure 5.5.1. General synthetic scheme of the DNA aptamer-DBCO.   
 
Anti-TNFα DNA aptamer-DBCO (7). The anti-TNFα DNA aptamer, possessing a 
protected thiol group on its 5’-terminus and prepared by general solid-phase 
oligonucleotide synthesis, was purchased from GeneDesign, Inc. Protected anti-TNFα 
DNA aptamer (28.8 mg, 3.55 μmol) was dissolved in 5.77 mL of water. To this solution, 
1 mM ethylenediaminetetraacetic acid (EDTA) in 10 mM Tris-HCl (23.1 mL, pH 8.0), 
0.12 M aqueous dithiothreitol (DTT) solution (19.2 mL), and 0.5 M sodium phosphate 
buffer (pH 8.0, 9.6 mL) were added, and then mixed overnight at ambient temperature. 
The buffer of the reaction mixture was exchanged to water by repeated ultrafiltration with 
Amicon Ultra-15 (3k MWCO, Merck Millipore) and dilution with water. To the resultant 
solution, 88.8 μL of dibenzocyclooctyne-maleimide (DBCO-maleimide, Tokyo Chemical 
Industries, 40 mM in DMSO, 3.55 μmol) and 600 μL of DMSO was added and mixed 
overnight at ambient temperature. The buffer of the reaction mixture was exchanged to 
water by repeated ultrafiltration with Amicon Ultra-15 (3k MWCO, Merck Millipore) and 
dilution with water. The resultant solution was freeze-dried, resulting in anti-TNFα DNA 
aptamer-DBCO (21.1 mg, 2.51 μmol, 71% yield). ESI-TOFMS (m/z): calculated for 
C276H339N106O154P25S 8411.67; found, 2101.90 ([M-4H]4-) and 1681.31 ([M-5H]5-).   
 
79
 
 
Anti-VEGF DNA aptamer-DBCO (8). Anti-VEGF DNA aptamer, possessing a 
protected thiol group on its 5’-terminus and prepared by general solid-phase 
oligonucleotide synthesis, was purchased from GeneDesign, Inc. Using 22.8 mg (2.74 
μmol) of anti-VEGF DNA aptamer with thiol-protection, anti-VEGF DNA aptamer-
DBCO (24.7 mg, quantitative yield) was obtained in a similar manner. ESI-TOFMS (m/z): 
calculated for C283H351N105O159P26S 8604.81; found, 2150.14 ([M-4H]4-) and 1719.90 
([M-5H]5-).   
 
Anti-TNFα DNA aptamer-Fc. To a solution of N3-Fc (6.6 μL, 7.58 mg/mL, 50 μg), 0.1 
M sodium phosphate buffer (pH 7.0, 24.4 μL) and 2.5 mM aqueous anti-TNFα DNA 
aptamer-DBCO solution (7.4 μL, 18.5 nmol) were added and shaken overnight at 25 ºC, 
resulting in anti-TNFα DNA aptamer -Fc. The reaction mixture was analyzed by SDS-
PAGE (Mini-PROTEAN TGX gel, 4 to 20%, Bio-Rad) in reducing conditions, and the 
gel was sequentially stained with SYPRO Ruby (Invitrogen) for proteins, and SYBR Safe 
(Invitrogen) for DNAs. The bands were detected by two conditions; (1) an excitation 
wavelength of 520 nm and emission filter of 605BP40, (2) an excitation wavelength of 
460 nm and emission filter of 525BP20. The band shift corresponding to an increase in 
molecular weight by conjugation was observed, and the band of the adduct was stained 
by both protein staining (Figure 2.4.5 (A)), and DNA staining (Figure 2.4.5 (B)), as seen 
in the graphic overlay (Figure 2.4.5 (C)). 
 
Anti-VEGF DNA aptamer-Fc. N3-Fc (50 μg) was conjugated with anti-VEGF DNA 
aptamer-DBCO (18.5 nmol) in a similar manner, resulting in anti-VEGF DNA aptamer-
Fc. SDS-PAGE analysis in the conditions described above resulted in similar results to 
the anti-TNFα DNA aptamer-Fc (protein staining (Figure 2.4.5 (D)), DNA staining 
(Figure 2.4.5 (E)), and graphic overlay (Figure 2.4.5 (F))). 
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5.6 Pharmacokinetic Studies of the Exenatide-Fc Fusion Compound 
 
Pharmacokinetic Studies of Exenatide and Exenatide-Fc 
Materials. Exenatide was prepared by solid-phase peptide synthesis according to the 
general Fmoc method. Exenatide-Fc was prepared as described above and stocked under 
cryogenic conditions. Exenatide (2.50 μmol/L) and Exenatide-Fc (0.313, 1.25, and 2.50 
μmol/L) solutions were prepared by dissolving and then diluting the compounds with D-
PBS(-) immediately before injection. 
Animals. All studies were approved by the Animal Care and Use Committee of the 
Pharmacokinetics and Bioanalysis Center of Shin Nippon Biomedical Laboratories, Ltd. 
Five-week-old male C57BL/6J mice were purchased from Charles River Laboratories 
Japan, Inc. (Yokohama, Japan). The animals had free access to food (CRF-1, Oriental 
Yeast Co., Ltd.) and water and were maintained under a 12:12-h light-dark cycle, 22 ± 
3 °C, and 50 ± 20% humidity. Animals whose weight differed slightly from the median 
value after acclimatization were selected and divided into four groups (corresponding to 
doses of 25.0 nmol/kg of Exenatide and 3.13, 12.5, and 25.0 nmol/kg of Exenatide-Fc) 
based on body weight. After grouping, six animals were housed per cage. 
Experimental Procedure. Injection solutions of Exenatide or Exenatide-Fc (10 mL/kg) 
were administered to 6-week-old mice intraperitoneally (n = 3 for each material, dose, 
and sampling time). Blood samples (ca. 0.6 mL) were collected from the posterior aorta 
1, 2, 8, 24, 48, 72, 96, 120, and 168 h after administration under anesthesia by isoflurane 
inhalation. Aprotinin (more than 500 KIU per 1 mL of blood) was added to each blood 
sample, and plasma was separated by centrifugation (4 °C, 10,000 × g, 5 min, Sorvall 
Legend Micro 21R microcentrifuge, Thermo Fisher Scientific) and stored in a deep 
freezer (below -70 °C) until analysis. 
Analysis. Plasma concentrations of Exenatide or Exenatide-Fc were analyzed in duplicate 
using the Exendin-4 EIA kit (Catalog no. S-1310, Peninsula Laboratories International, 
Inc.) according to the manufacturer’s protocol. Briefly, the antiserum solution in EIA 
buffer was dispensed to each well of the immunoplate, which was then incubated at 25 °C 
for 1 h. Plasma samples diluted 10-fold with PBS-Tween®20 or standard solutions (50 
μL each) were added to each well, and the immunoplate was incubated at 25 °C for an 
additional 2 h. Subsequently, biotinylated tracer solution in EIA buffer (25 μL) was added 
to each well, and the immunoplate was then incubated at 4 °C overnight. After washing 
all wells with EIA buffer (300 μL, 5 times), streptavidin-horse radish peroxidase solution 
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(100 μL) was added, and the immunoplate was incubated at 25 °C for 1 h. After washing 
all wells with EIA buffer (300 μL, five times), 3,3',5,5'-tetramethylbenzidine substrate 
solution (100 μL) was added, and the immunoplate was incubated at 25 °C for 7.5 min. 
Stop solution (2 M HCl, 100 μL) was added, and the immunoplate was read at 450 nm in 
a Multiskan Ascent plate reader (LabSystems). Standard curves of Exenatide and 
Exenatide-Fc were generated by 4-parameter logistic curve fitting. The quantitative range 
of Exenatide was 0.1580 to 79.00 nmol/L (as concentration in plasma) and that of 
Exenatide-Fc was 1.580 to 158.0 nmol/L. The pharmacokinetic parameters were 
calculated using the Phoenix WinNonlin 7.0 software (Certara). 
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5.7 Surface Plasmon Resonance Experiments of Exenatide-Fc Fusion Compound 
and Trastuzumab 
 
Surface plasmon resonance experiments. Surface plasmon resonance (SPR) 
experiments were conducted at 25 ºC using a Biacore T200 instrument (GE Healthcare). 
As assay buffers, 20 mM phosphate buffer (pH 6.0 or 7.4) containing 150 mM of NaCl 
and 0.05% surfactant P20 (GE Healthcare) were used. Biotinylated human FcRn 
(Immunitrack ApS) was immobilized on a Biacore Sensor Chip CAP according to the 
manufacturer’s protocol. An immobilization level of 80~100 response units (RU) was 
reached. Trastuzumab was diluted to concentrations ranging from 8100 nM to 100 nM, 
and Exenatide-Fc was diluted from 1920 nM to 20 nM with assay buffer just before use. 
The solutions were injected over flow cells immobilized with human FcRn or assay buffer 
as a blank. The association and dissociation phases were set to 120 s with 30 μL/min of 
flow rate. The sensorgram data were processed by subtracting the signals of blank cells. 
Binding analysis was performed using the Biacore T200 Evaluation Software (GE 
Healthcare), and affinity parameters were calculated based on steady-state analysis.  
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5.8 In vitro Biological Activities of Exenatide-Fc Fusion Compound 
 
In vitro Evaluation of Biological Activities of Exenatide and Exenatide-Fc 
Cell-based Human GLP-1 Receptor/cAMP Assay. X. laevis melanophore cells 
expressing the human GLP-1 receptor were seeded in a 96-well plate at a concentration 
of 0.8 × 105 cells/well and cultured in Leibovitz’s L-15 culture medium (Thermo Fisher 
Scientific) containing 0.2% BSA for 48 h. After pre-cultivation, the culture medium was 
removed. Melatonin (Sigma-Aldrich Corp.) solution (2 nM) was added, and after 
cultivation at 25 °C for 1 h, the absorbance of each well at 620 nm [A620(a)] was measured. 
Subsequently, Exenatide or Exenatide-Fc was added to the culture medium, and after 
cultivation at 25 °C for 1 h, the absorbance [A620(b)] was measured again. GLP-1 activity 
was calculated using the following equation: 
GLP-1 activity (a.u.) = [A620(b) − A620(a)]/A620(a). 
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5.9 Pharmacodynamic Studies of Exenatide-Fc Fusion Compound 
 
Pharmacodynamic Studies of Exenatide and Exenatide-Fc 
Animals. All studies were approved by the Animal Care and Use Committee of 
Ajinomoto Co., Inc. Five-week-old male BKS.Cg-Dock7m+/+Leprdb/J mice (db/db mice) 
were purchased from Charles River Laboratories Japan, Inc. One animal was housed per 
cage and maintained under a 12:12-h light-dark cycle, 22 ± 1 °C, and 55 ± 5% humidity. 
The animals had free access to food (CRF-1, Oriental Yeast Co., Ltd.) and water 
throughout the acclimatization and experimental periods. After acclimatization for one 
week, body weight and blood glucose levels (via the tail vein) were measured one day 
before dosing. The animals were divided into five groups (corresponding to doses of 25.0 
nmol/kg of Exenatide, 3.13, 12.5, and 25.0 nmol/kg of Exenatide-Fc, and placebo) based 
on equality of body weight and blood glucose levels. 
Experimental Procedure. Exenatide (2.50 μmol/L) and Exenatide-Fc (0.313, 1.25, and 
2.50 μmol/L) solutions were prepared by dissolving and then diluting the compounds with 
D-PBS(-) immediately before injection. Injection solutions of Exenatide, Exenatide-Fc, 
or PBS (10 mL/kg) were administered to six-week-old mice intraperitoneally (n = 5 for 
each material and dose). Blood samples were collected via the tail vein 1, 2, 8, 24, 48, 72, 
and 168 h after administration, and blood glucose levels were measured using the Accu-
Chek® blood glucose meter (Roche Diabetes Care). 
 
  
85
 
 
 
 
 
 
 
 
CHAPTER 6 
 
 
 
References 
 
 
 
  
 
6. References 
(1) Uhlig, T., Kyprianou, T., Martinelli, F. G., Oppici, C. A., Heiligers, D., Hills, D., 
Calvo, X. R., and Verhaert, P. (2014) The emergence of peptides in the 
pharmaceutical business: from exploration to exploitation. EuPA Open 
Proteomics 4, 58–69. 
(2) Fosgerau, K., and Hoffmann, T. (2015) Peptide therapeutics: current status and 
future directions. Drug Discov. Today 20, 122–128. 
(3) Singh, J., Kaur, H., Kaushik, A., and Peer, S. (2011) A review of antisense 
therapeutic interventions for molecular biological targets in various diseases. Int. 
J. Pharmacol. 7, 294–315. 
(4) Lundin, K. E., Gissberg, O., and Smith, C. I. E. (2015) Oligonucleotide therapies: 
the past and the present. Hum. Gene Ther. 26, 475–485. 
(5) Lau, J. L., and Dunn, M. K. (2018) Therapeutic peptides: historical perspectives, 
current development trends, and future directions. Bioorgan. Med. Chem. 26, 
2700–2707. 
(6) Schally, A. V., Arimura, A., Kastin, A. J., Matsuo, H., Baba, Y., Redding, T. W., 
Nair, R. M. G., Debeljuk, L., and White, W. F. (1971) Gonadotropin-releasing 
hormone: one polypeptide regulates secretion of luteinizing and follicle-
stimulating hormones. Science 173, 1036–1038. 
(7) Riniker, B., Neher, R., Maier, R., Kahnt, F. W., Byfield, P. G. H., Gudmundsson, 
T. V., Galante, L., and Macintyre, I. (1968) Menschliches Calcitonin I. Isolierung 
und Charakterisierung. Helvetica Chimica Acta 51, 1738–1742. 
(8) Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., and Guillemin, 
R. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive 
pituitary growth hormone. Science 179, 77–79. 
(9) Flynn, T. G., de Bold, M. L., and de Bold, A. J. (1983) The amino acid sequence 
of an atrial peptide with potent diuretic and natriuretic properties. Biochem. 
Biophys. Res. Commun. 117, 859–865. 
(10) Kangawa, K., and Matsuo, H. (1984) Purification and complete amino acid 
sequence of α-human atrial natriuretic polypeptide (α-hANP). Biochem. Biophys. 
Res. Commun. 118, 131–139. 
(11) Eng, J., Kleinman, W. A., Singh, L., Singh, G., and Raufman, J. P. (1992) Isolation 
and characterization of exendin-4, an exendin-3 analogue, from heloderma 
suspectum venom. Further evidence for an exendin receptor on dispersed acini 
from guinea pig pancreas. J. Biol. Chem. 267, 7402–7405. 
(12) Wang, L., Brock, A., Herberich, B., and Schultz, P. G. (2001) Expanding the 
87
 
genetic code of Escherichia coli. Science 292, 498–500. 
(13) Sakamoto, K., Hayashi, A., Sakamoto, A., Kiga, D., Nakayama, H., Soma, A., 
Kobayashi, T., Kitabatake, M., Takio, K., Saito, K., et al. (2002) Site-specific 
incorporation of an unnatural amino acid into proteins in mammalian cells. 
Nucleic Acids Res. 30, 4692–4699. 
(14) Ohuchi, M., Murakami, H., and Suga, H. (2007) The flexizyme system: a highly 
flexible tRNA aminoacylation tool for the translation apparatus. Curr Opin Chem 
Biol 11, 537-42. 
(15) Tapeinou, A., Matsoukas, M. T., Simal, C., and Tselios, T. (2015) Review cyclic 
peptides on a merry-go-round; towards drug design. Biopolymers 104, 453–61. 
(16) Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., and Qiao, L. 
(2016) Aptamers: a promising chemical antibody for cancer therapy. Oncotarget 
7, 13446-13463. 
(17) Kong, H. Y., and Byun, J. (2013) Nucleic acid aptamers: new methods for 
selection, stabilization, and application in biomedical science. Biomol. Ther. 21, 
423–434. 
(18) Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., and Zu, Y. (2014) 
Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol. Ther. 
Nucleic Acids 3, e182. 
(19) Ku, T. H., Zhang, T., Luo, H., Yen, T. M., Chen, P. W., Han, Y., and Lo, Y. H. 
(2015) Nucleic acid aptamers: an emerging tool for biotechnology and biomedical 
sensing. Sensors 15, 16281–16313. 
(20) Strohl, W. R. (2015) Fusion proteins for half-life extension of biologics as a 
strategy to make biobetters. BioDrugs 29, 215–239. 
(21) van Witteloostuijn, S. B., Pedersen, S. L., and Jensen, K. J. (2016) Half-life 
extension of biopharmaceuticals using chemical methods: alternatives to 
PEGylation. ChemMedChem 11, 2474–2495. 
(22) Kontermann, R. E. (2016) Half-life extended biotherapeutics. Expert Opin. Biol. 
Ther. 16, 903–915. 
(23) Schmidt, S. R. (2013) Fusion proteins for half-life extension. Fusion Protein 
Technologies for Biopharmaceuticals: Applications and Challenges (Schmidt, S. 
R., Ed.) pp 91–106, Chapter 6, John Wiley & Sons, Inc., New Jersey. 
(24) Heard, K. R., Wu, W., Li, Y., Zhao, P., Woznica, I., Lai, J. H., Beinborn, M., 
Sanford, D. G., Dimare, M. T., Chiluwal, A. K., et al. (2013) A general method for 
making peptide therapeutics resistant to serine protease degradation: application 
to dipeptidyl peptidase IV substrates. J. Med. Chem. 56, 8339–8351. 
88
 
(25) Manandhar, B., and Ahn, J.-M. (2015) Glucagon-like peptide-1 (GLP-1) analogs: 
recent advances, new possibilities, and therapeutic implications. J. Med. Chem. 
58, 1020–1037. 
(26) Geary, R. S., Norris, D., Yu, R., and Bennett, C. F. (2015) Pharmacokinetics, 
biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Delivery 
Rev. 87, 46‒51. 
(27) Meibohm, B., and Zhou, H. (2012) Characterizing the impact of renal impairment 
on the clinical pharmacology of biologics. J. Clin. Pharmacol. 52, 54S–62S. 
(28) Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G., and Richette, P. (2012) 
Antibodies against polyethylene glycol in healthy subjects and in patients treated 
with PEG-conjugated agents. Expert Opin. Drug Delivery 9, 1319–1323. 
(29) Podust, V. N., Balan, S., Sim, B.-C., Coyle, M. P., Ernst, U., Peters, R. T., and 
Schellenberger, V. (2016) Extension of in vivo half-life of biologically active 
molecules by XTEN protein polymers. J. Control. Release 240, 52–66. 
(30) Schlapschy, M., Binder, U., Börger, C., Theobald, I., Wachinger, K., Kisling, S., 
Haller, D., and Skerra, A. (2013) PASylation: a biological alternative to 
PEGylation for extending the plasma half-life of pharmaceutically active proteins. 
Protein Eng. Des. Sel. 26, 489–501. 
(31) Binder, U., and Skerra, A. (2017) PASylation®: a versatile technology to extend 
drug delivery. Curr. Opin. Colloid Interface Sci. 31, 10–17. 
(32) Rajpal, A., Strop, P., Yeung, Y. A., Chaparro-Riggers, J., and Pons, J. (2013) 
Introduction: antibody structure and function. Therapeutic Fc-Fusion Proteins 
(Chamow, S. M., Ryll, T., Lowman, H. B., and Farson, D., Eds.) pp 1–44, Chapter 
1, Wiley-VCH, Weinheim. 
(33) Levin, D., Golding, B., Strome, S. E., and Sauna, Z. E. (2015) Fc fusion as a 
platform technology: potential for modulating immunogenicity. Trends 
Biotechnol. 33, 27–34. 
(34) Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, 
H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., et al. (1989) Designing 
CD4 immunoadhesins for AIDS therapy. Nature 337, 525–531. 
(35) Frampton, J. E., and Lyseng-Williamson, K. A. (2009) Romiplostim. Drugs 69, 
307–317. 
(36) Benjamin, W. U., and Sun, Y.-N. (2014) Pharmacokinetics of peptide-Fc fusion 
proteins. J. Pharm. Sci. 103, 53–64. 
(37) Kugler, A. J., and Thiman, M. L. (2018) Efficacy and safety profile of once-
89
 
weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes, 
Metab. Syndr. Obes. 11, 187–197. 
(38) Shimamoto, G., Gegg, C., Boone, T., and Queva, C. (2012) Peptibodies: a flexible 
alternative format to antibodies. mAbs 4, 586–591. 
(39) Peplow, M. (2019) Click chemistry targets antibody-drug conjugates for the clinic. 
Nat. Biotechnol. 37, 835–839. 
(40) Stefano, J. E., Busch, M., Hou, L., Park, A., and Gianolio, D. A. (2013) Micro- 
and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge 
region thiols for tumor targeting. Antibody-Drug Conjugates. Methods in 
Molecular Biology (Methods and Protocols) (Ducry, L., Ed.) pp 145–171, 9, 
Humana Press, Totowa, NJ. 
(41) Mezo, A. R., McDonnell, K. A., Low, S. C., Song, J., Reidy, T. J., Lu, Q., Amari, 
J. V., Hoehn, T., Peters, R. T., Dumont, J., et al. (2012) Atrial natriuretic peptide-
Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics 
in rats. Bioconj. Chem. 23, 518–526. 
(42) Muir, T. W., Sondhi, D., and Cole, P. A. (1998) Expressed protein ligation: a 
general method for protein engineering. Proc. Nat. Acad. Sci. 95, 6705–6710. 
(43) Vila-Perelló, M., Liu, Z., Shah, N. H., Willis, J. A., Idoyaga, J., and Muir, T. W. 
(2013) Streamlined expressed protein ligation using split inteins. J. Am. Chem. 
Soc. 135, 286–292. 
(44) Frutos, S., Jordan, J. B., Bio, M. M., Muir, T. W., Thiel, O. R., and Vila-Perelló, 
M. (2016) Access to site-specific Fc–cRGD peptide conjugates through 
streamlined expressed protein ligation. Org. Biomol. Chem. 14, 9549–9553. 
(45) Thanos, C. D., McEvoy, L., Penta, K., Baliga, R., Bajad, S., Pollitt, S., Murray, 
C., Steiner, A., and Gill, A.; MODIFIED Fc PROTEINS COMPRISING SITE-
SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF 
THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF 
THEIR USE. WO 2014/004639 A1, 3 January, 2014. 
(46) Kim, Y.-M., Bae, S.-M., Kim, D.-J., Song, D.-H., Lim, C.-K., Kwon, S.-C., and 
Lee, G.-S.; IMMUNOGLOBULIN Fc FRAGMENT MODIFIED BY NON-
PEPTIDE POLYMER AND PHARMACEUTICAL COMPOSITION 
COMPRISING THE SAME. WO 2006/107124 A1, 12 October, 2006. 
(47) Hermanson, G. T. (2008) Functional targets. Bioconjugate Techniques (Second 
Edition) (Hermanson, G. T., Ed.) pp 1–168, 1, Academic Press, New York. 
(48) Iwamoto, M., Yamaguchi, T., Sekiguchi, Y., Oishi, S., Shiiki, T., Soma, M., 
Nakamura, K., Yoshida, M., Chaya, H., Mori, Y., et al. (2018) Pharmacokinetic 
90
 
and pharmacodynamic profiles of glyco-modified atrial natriuretic peptide 
derivatives synthesized using chemo-enzymatic synthesis approaches. Bioconj. 
Chem. 29, 2829–2837. 
(49) Yagi, Y., and Suzuki, S. (2013) Characterization of oligosaccharides in therapeutic 
antibodies. Chromatography 34, 83–88. 
(50) Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, 
D., Lai, J., Stadlen, A., Li, B., et al. (2001) High resolution mapping of the binding 
site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 
variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591–6604. 
(51) Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., 
Kawanishi, T., and Yamaguchi, T. (2010) Importance of neonatal FcR in 
regulating the serum half-life of therapeutic proteins containing the Fc domain of 
human IgG1: a comparative study of the affinity of monoclonal antibodies and 
Fc-fusion proteins to human neonatal FcR. J. Immunol. 184, 1968–1976. 
(52) White, D. R., Khedri, Z., Kiptoo, P., Siahaan, T. J., and Tolbert, T. J. (2017) 
Synthesis of a bifunctional peptide inhibitor–IgG1 Fc fusion that suppresses 
experimental autoimmune encephalomyelitis. Bioconj. Chem. 28, 1867–1877. 
(53) Fung, A. W. S., and Fahlman, R. P. (2015) The molecular basis for the post-
translational addition of amino acids by L/F transferase in the N-end rule pathway. 
Curr. Protein Pept. Sci. 16, 163–180. 
(54) Ebisu, K., Tateno, H., Kuroiwa, H., Kawakami, K., Ikeuchi, M., Hirabayashi, J., 
Sisido, M., and Taki, M. (2009) N-Terminal specific point-immobilization of 
active proteins by the one-pot NEXT-A method. ChemBioChem 10, 2460–2464. 
(55) Hamamoto, T., Sisido, M., Ohtsuki, T., and Taki, M. (2011) Synthesis of a cyclic 
peptide/protein using the NEXT-A reaction followed by cyclization. Chem. 
Commun. 47, 9116–9118. 
(56) Taki, M., and Kuroiwa, H. (2015) Unexpectedly fast transfer of positron-emittable 
artificial substrate into N-terminus of peptide/protein mediated by wild-type L/F-
tRNA-protein transferase. Amino Acids 47, 1279–1282. 
(57) Kinstler, O. B., Brems, D. N., Lauren, S. L., Paige, A. G., Hamburger, J. B., and 
Treuheit, M. J. (1996) Characterization and stability of N-terminally PEGylated 
rhG-CSF. Pharm. Res. 13, 996–1002. 
(58) Agten, S. M., Dawson, P. E., and Hackeng, T. M. (2016) Oxime conjugation in 
protein chemistry: from carbonyl incorporation to nucleophilic catalysis. J. Pept. 
Sci. 22, 271–279. 
(59) Zhang, L., and Tam, J. P. (1996) Thiazolidine formation as a general and site-
91
 
specific conjugation method for synthetic peptides and proteins. Anal. Biochem. 
233, 87–93. 
(60) Dawson, P. E., Muir, T. W., Clark-Lewis, I., and Kent, S. B. H. (1994) Synthesis 
of proteins by native chemical ligation. Science 266, 776–779. 
(61) Conibear, A. C., Watson, E. E., Payne, R. J., and Becker, C. F. W. (2018) Native 
chemical ligation in protein synthesis and semi-synthesis. Chem. Soc. Rev. 47, 
9046–9068. 
(62) Tanaka, T., Kamiya, N., and Nagamune, T. (2005) N-terminal glycine-specific 
protein conjugation catalyzed by microbial transglutaminase. FEBS Lett. 579, 
2092–2096. 
(63) Theile, C. S., Witte, M. D., Blom, A. E. M., Kundrat, L., Ploegh, H. L., and 
Guimaraes, C. P. (2013) Site-specific N-terminal labeling of proteins using 
sortase-mediated reactions. Nat. Protoc. 8, 1800–1807. 
(64) Weeks, A. M., and Wells, J. A. (2017) Engineering peptide ligase specificity by 
proteomic identification of ligation sites. Nat. Chem. Biol. 14, 50–57. 
(65) Podust, V. N., Sim, B.-C., Kothari, D., Henthorn, L., Gu, C., Wang, C.-W., 
McLaughlin, B., and Schellenberger, V. (2013) Extension of in vivo half-life of 
biologically active peptides via chemical conjugation to XTEN protein polymer. 
Protein Eng. Des. Sel. 26, 743–753. 
(66) Sur, S., Qiao, Y., Fries, A., O’Meally, R. N., Cole, R. N., Kinzler, K. W., Vogelstein, 
B., and Zhou, S. (2015) PRINT: a protein bioconjugation method with exquisite 
N-terminal specificity. Sci. Rep. 5, 18363. 
(67) Zhao, Z. G., Im, J. S., Lam, K. S., and Lake, D. F. (1999) Site-specific 
modification of a single-chain antibody using a novel glyoxylyl-based labeling 
reagent. Bioconj. Chem. 10, 424-430. 
(68) Soundrarajan, N., Sokalingam, S., Raghunathan, G., Budisa, N., Paik, H.-J., Yoo, 
T. H., and Lee, S.-G. (2012) Conjugation of proteins by installing bio-
orthogonally reactive groups at their N-termini. PLoS One 7, e46741. 
(69) Lang, K., and Chin, J. W. (2014) Bioorthogonal reactions for labeling proteins. 
ACS Chem. Biol. 9, 16–20. 
(70) Knop, F. K., Brønden, A., and Vilsbøll, T. (2017) Exenatide: pharmacokinetics, 
clinical use, and future directions. Expert Opin. Pharmacother. 18, 555–571. 
(71) Mongiat-Artus, P., and Teillac, P. (2004) Abarelix: the first gonadotrophin-
releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. 
Pharmacother. 5, 2171–2179. 
(72) Haubner, R., Gratias, R., Diefenbach, B., Goodman, S. L., Jonczyk, A., and 
92
 
Kessler, H. (1996) Structural and functional aspects of RGD-containing cyclic 
pentapeptides as highly potent and selective integrin αVβ3 antagonists. J. Am. 
Chem. Soc. 118, 7461–7472. 
(73) Kantlehner, M., Finsinger, D., Meyer, J., Schaffner, P., Jonczyk, A., Diefenbach, 
B., Nies, B., and Kessler, H. (1999) Selective RGD-mediated adhesion of 
osteoblasts at surfaces of implants. Angew. Chem. Int. Ed. 38, 560–562. 
(74) Orava, E. W., Jarvik, N., Shek, Y. L., Sidhu, S. S., and Gariépy, J. (2013) A short 
DNA aptamer that recognizes TNFα and blocks its activity in vitro. ACS Chem. 
Biol. 8, 170–178. 
(75) Potty, A. S. R., Kourentzi, K., Fang, H., Jackson, G. W., Zhang, X., Legge, G. B., 
and Willson, R. C. (2009) Biophysical characterization of DNA aptamer 
interactions with vascular endothelial growth factor. Biopolymers 91, 145–156. 
(76) Groff, K., Brown, J., and Clippinger, A. J. (2015) Modern affinity reagents: 
recombinant antibodies and aptamers. Biotechnol. Adv. 33, 1787–1798. 
(77) Qi, Y., Simakova, A., Ganson, N. J., Li, X., Luginbuhl, K. M., Ozer, I., Liu, W., 
Hershfield, M. S., Matyjaszewski, K., and Chilkoti, A. (2016) A brush-
polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and 
eliminates poly(ethylene glycol) antigenicity. Nat. Biomed. Eng. 1, 0002. 
(78) Chen, W., Wang, G., Yung, B. C., Liu, G., Qian, Z., and Chen, X. (2017) Long-
acting release formulation of exendin-4 based on biomimetic mineralization for 
type 2 diabetes therapy. ACS Nano 11, 5062–5069. 
(79) Schellenberger, V., Wang, C.-W., Geething, N. C., Spink, B. J., Campbell, A., To, 
W., Scholle, M. D., Yin, Y., Yao, Y., Bogin, O., et al. (2009) A recombinant 
polypeptide extends the in vivo half-life of peptides and proteins in a tunable 
manner. Nat. Biotechnol. 27, 1186. 
(80) Neuber, T., Frese, K., Jaehrling, J., Jäger, S., Daubert, D., Felderer, K., Linnemann, 
M., Höhne, A., Kaden, S., Kölln, J., et al. (2014) Characterization and screening 
of IgG binding to the neonatal Fc receptor. mAbs 6, 928–942. 
(81) Abdiche, Y. N., Yeung, Y. A., Chaparro-Riggers, J., Barman, I., Strop, P., Chin, S. 
M., Pham, A., Bolton, G., McDonough, D., Lindquist, K., et al. (2015) The 
neonatal Fc receptor (FcRn) binds independently to both sites of the IgG 
homodimer with identical affinity. mAbs 7, 331–343. 
(82) Lu, L., Su, X., Wang, Y., Luo, Y., Yang, J., Xie, L., Gao, X., Ma, Y., Tian, Y., Yuan, 
F., et al. (2017) In vitro and in vivo characterization of a novel long-acting GLP-
1 receptor agonist, exendin-4–Fc fusion protein. RSC Adv. 7, 54178–54187. 
(83) Potenza, M. N., and Lerner, M. R. (1992) A rapid quantitative bioassay for 
93
 
evaluating the effects of ligands upon receptors that modulate cAMP levels in a 
melanophore cell line. Pigm. Cell Melanoma Res. 5, 372–378. 
(84) Coleman, D. L. (1978) Obese and diabetes: two mutant genes causing diabetes-
obesity syndromes in mice. Diabetologia 14, 141–148. 
(85) Kobayashi, K., Forte, T. M., Taniguchi, S., Ishida, B. Y., Oka, K., and Chan, L. 
(2000) The db/db mouse, a model for diabetic dyslipidemia: molecular 
characterization and effects of western diet feeding. Metabolism 49, 22–31. 
(86) Glaesner, W., Vick, A. M., Millican, R., Ellis, B., Tschang, S. H., Tian, Y., Bokvist, 
K., Brenner, M., Koester, A., Porksen, N., et al. (2010) Engineering and 
characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, 
an Fc fusion protein. Diabetes Metab. Res. Rev. 26, 287–296. 
(87) Abramochkin, G., and Shrader, T. E. (1995) The leucyl/phenylalanyl-tRNA-
protein transferase: overexpression and characterization of substrate recognition, 
domain structure, and secondary structure. J. Biol. Chem. 270, 20621–20628. 
(88) Taki, M., Kuno, A., Matoba, S., Kobayashi, Y., Futami, J., Murakami, H., Suga, 
H., Taira, K., Hasegawa, T., and Sisido, M. (2006) Leucyl/phenylalanyl-tRNA-
protein transferase-mediated chemoenzymatic coupling of N-terminal Arg/Lys 
units in post-translationally processed proteins with non-natural amino acids. 
ChemBioChem 7, 1676–1679. 
(89) Datta, D., Wang, P., Carrico, I. S., Mayo, S. L., and Tirrell, D. A. (2002) A 
designed phenylalanyl-tRNA synthetase variant allows efficient in vivo 
incorporation of aryl ketone functionality into proteins. J. Am. Chem. Soc. 124, 
5652–5653. 
(90) Wadzack, J., Bittner, J. U., Nierhaus, K. H., Jünemann, R., Triana-Alonso, F. J., 
Caillet, J., Meinnel, T., and Vanatalu, K. (1996) In vivo deuteration of transfer 
RNAs: overexpression and large-scale purification of deuterated specific tRNAs. 
Nucleic Acids Res. 24, 907–913. 
(91) Capon, D. J., Kaneko, N., Yoshimori, T., Shimada, T., Wurm, F. M., Hwang, P. K., 
Tong, X., Adams, S. A., Simmons, G., Sato, T., et al. (2011) Flexible antibodies 
with nonprotein hinges. Proc. Jpn. Acad., Ser. B 87, 603–616. 
(92) Cheng, Z., Elias, D. R., Kamat, N. P., Johnston, E. D., Poloukhtine, A., Popik, V., 
Hammer, D. A., and Tsourkas, A. (2011) Improved tumor targeting of polymer-
based nanovesicles using polymer–lipid blends. Bioconj. Chem. 22, 2021–2029. 
(93) Debets, M. F., van Berkel, S. S., Schoffelen, S., Rutjes, F. P. J. T., van Hest, J. C. 
M., and van Delft, F. L. (2010) Aza-dibenzocyclooctynes for fast and efficient 
enzyme PEGylation via copper-free (3+2) cycloaddition. Chem. Commun. 46, 
94
 
97–99. 
(94) Chan, W. C., and White, P. D. (2000) Basic procedures. Fmoc Solid-Phase Peptide 
Synthesis: A Practical Approach (Chan, W. C., and White, P. D., Eds.) pp 41–76, 
Chapter 3, Oxford University Press, New York. 
(95) Hong, V., Presolski, S. I., Ma, C., and Finn, M. G. (2009) Analysis and 
optimization of copper-catalyzed azide–alkyne cycloaddition for bioconjugation. 
Angew. Chem., Int. Ed. 48, 9879–9883. 
(96) Hein, J. E., Krasnova, L. B., Iwasaki, M., and Fokin, V. V. (2011) Cu-catalyzed 
azide-alkyne cycloaddition: preparation of tris((1-benzyl-1H-1,2,3-
triazolyl)methyl)amine. Org. Synth. 88, 238–246. 
(97) Ghosh, P. S., and Hamilton, A. D. (2012) Supramolecular dendrimers: convenient 
synthesis by programmed self-assembly and tunable thermoresponsivity. Chem. 
Eur. J. 18, 2361–2365. 
 
95
 
List of Publications and Presentations 
 
Article 
Hirasawa, Shigeo; Kitahara, Yoshiro; Okamatsu, Yoriko; Fujii, Tomohiro; Nakayama, 
Akira; Ueno, Satoko; Ijichi, Chiori; Futaki, Fumie; Nakata, Kunio; Taki, Masumi (2019) 
Facile and Efficient Chemoenzymatic Semisynthesis of Fc-Fusion Compounds for Half-
Life Extension of Pharmaceutical Components. Bioconjugate Chemistry 30, 2323-2331; 
front cover article. 
 
 
Presentations 
Hirasawa, S.; Kitahara, Y.; Okamatsu, Y.; Nakayama, A.; Ueno, S.; Taki, M.; Half-Life 
Extension Technology Using Semi-Synthetic Fc-Fusions. 18th Annual PEPTALK, San 
Diego, CA, USA, 14th to 18th January 2019.  
 
Hirasawa, S.; Kitahara, Y.; Okamatsu, Y.; Nakayama, A.; Ueno, S.; Taki, M.; Half-Life 
Extension Technology Using Semi-Synthetic Fc-Fusions. 15th Annual PEGS BOSTON, 
Boston, MA, USA, 8th to 12th April 2019.  
 
 
  
96
 
Acknowledgements 
 
I would like to start by thanking Prof. Masumi Taki for his enthusiastic and 
encouraging advice on this research. I was very happy to proceed with this research with 
him, and all the members in his laboratory were supportive.  
I thank Dr. Daisuke Ejima, Dr. Masayo Date, Dr. Masakazu Sugiyama, and Dr. 
Haruya Sato. When I first started research on bioconjugation reactions, they gave me a 
lot of useful and helpful advice on protein engineering.  
Thanks to Dr. Yoshiro Kitahara, Dr. Tomohiro Fujii, and Ms. Yoriko Okamatsu for 
the useful discussion and kind support on the evaluation of in vitro biological activity and 
pharmacodynamic studies.  
I also thank Dr. Akira Nakayama, Ms. Satoko Ueno, Dr. Chiori Ijichi, and Ms. 
Fumie Futaki of Ajinomoto Co. Inc, and Dr. Takahiro Nakamura, Dr. Takeshi Nakamura, 
Mr. Yoshifumi Kodama, and Ms. Tae Nishimatsu of Shin Nippon Biomedical 
Laboratories, Ltd. for the useful discussion and kind support on the pharmacokinetic 
studies.  
I thank Dr. Kunio Nakata for the kind support on the analyses of surface plasmon 
resonances and Ms. Tingting Zhang and Ms. Ruyu Li of GenScript Biotech Corp. for their 
assistance with the expression of Lys-Fc.  
I thank Dr. Kazutaka Shimbo and Ms. Reiko Yuji for the useful discussion on mass 
spectrometry and Mr. Syohei Ifuku for his dedicated support on the syntheses of peptide 
materials.  
I thank the late Prof. Knud Hermann Nierhaus of the Max Planck Institute for 
Molecular Genetics for the kind gift of the pPhe plasmid and MRE600rif E. coli strain. I 
sincerely hope that his soul rests in peace.  
     I would like to thank Editage (www.editage.com) for English language editing.  
Finally, I would like to thank my family. My wife, Kazuko, is supportive of my 
research carrier. And my son, Shin-ichiro, and daughter, Tomoka, always cheer me up.  
 
 
 
 
97
